
Congresos
Materiales de congresos
Tenga acceso a resúmenes, pósteres y presentaciones de los siguientes congresos
Enero 2025
ASCO-GI (Sociedad Estadounidense de Oncología Clínica - Simposio de Cánceres Gastrointestinales)
ASCO-GI (Sociedad Estadounidense de Oncología Clínica - Simposio de Cánceres Gastrointestinales)
January 2025 (San Francisco, CA)
Pósteres
Alternative dosing regimens of tislelizumab proposed using modeling and simulation
First-in-human, phase 1a, dose escalation study of BGB-B167, a CEA x 4-1BB bispecific antibody, as monotherapy or combined with tislelizumab (anti-PD-1), in patients with selected advanced or metastatic solid tumors
First-line (1L) tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT in advanced/metastatic esophageal squamous cell carcinoma (ESCC): RATIONALE-306 Japanese subgroup analysis with longer follow-up
Impact of tislelizumab + chemotherapy versus placebo + chemotherapy on patient-reported symptoms and disease progression by programmed death-ligand 1 expression in gastroesophageal adenocarcinoma: a post hoc analysis of the RATIONALE-305 trial
Impact of tislelizumab + chemotherapy versus placebo + chemotherapy on patient-reported symptoms and overall survival (OS) by programmed death-ligand 1 (PD-L1) expression in advanced or metastatic esophageal squamous cell carcinoma (ESCC): A post hoc analysis of the RATIONALE-306 trial
Response characteristics of tislelizumab (TIS) plus chemotherapy (chemo) in first-line (1L) treatment of locally advanced or metastatic esophageal squamous cell carcinoma (ESCC): a post hoc analysis of RATIONALE-306
Tislelizumab (TIS) + chemotherapy (chemo) vs placebo (PBO) + chemo as first-line (1L) treatment in gastric/gastroesophageal junction adenocarcinoma (GC/GEJC) patients with/without peritoneal or liver metastases: a post hoc analysis of RATIONALE-305 study
Resúmenes
Alternative dosing regimens of tislelizumab proposed using modeling and simulation
First-in-human, phase 1a, dose escalation study of BGB-B167, a CEA x 4-1BB bispecific antibody, as monotherapy or combined with tislelizumab (anti-PD-1), in patients with selected advanced or metastatic solid tumors
First-line (1L) tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT in advanced/metastatic esophageal squamous cell carcinoma (ESCC): RATIONALE-306 Japanese subgroup analysis with longer follow-up
Impact of tislelizumab + chemotherapy versus placebo + chemotherapy on patient-reported symptoms and disease progression by programmed death-ligand 1 expression in gastroesophageal adenocarcinoma: a post hoc analysis of the RATIONALE-305 trial
Impact of tislelizumab + chemotherapy versus placebo + chemotherapy on patient-reported symptoms and overall survival (OS) by programmed death-ligand 1 (PD-L1) expression in advanced or metastatic esophageal squamous cell carcinoma (ESCC): A post hoc analysis of the RATIONALE-306 trial
Response characteristics of tislelizumab (TIS) plus chemotherapy (chemo) in first- line (1L) treatment of locally advanced or metastatic esophageal squamous cell carcinoma (ESCC): a post hoc analysis of RATIONALE-306
Tislelizumab (TIS) + chemotherapy (chemo) vs placebo (PBO) + chemo as first-line (1L) treatment in gastric/gastroesophageal junction adenocarcinoma (GC/GEJC) patients with/without peritoneal or liver metastases: a post hoc analysis of RATIONALE-305 study.
Diciembre 2024
SABCS (Simposio sobre Cáncer de Mama de San Antonio)
SABCS (Simposio sobre Cáncer de Mama de San Antonio)
Diciembre de 2024 (San Antonio, Texas)
Pósteres
First-in-human phase 1a, dose-escalation study of BGB-43395 (CDK4-selective inhibitor) as monotherapy and in combination with fulvestrant or letrozole in patients with metastatic HR+/HER2− breast cancer and other advanced solid tumors
Preclinical characterization of BGB-43395, a potential best-in-class CDK4 selective inhibitor with potent pharmacodynamic and anti-tumor activity in HR+HER2- breast cancer models
Trial in progress: A first-in-human phase 1a/b, dose-escalation/expansion study of BG-68501/ETX-197 (CDK2 inhibitor) as monotherapy or in combination with fulvestrant for patients with HR+/HER2− breast cancer and other advanced solid tumors
Trial in progress: First-in-human phase 1a/1b, dose-escalation/expansion study of BGB-43395 (CDK4 selective inhibitor) as monotherapy or combination therapy in Chinese patients with metastatic HR+/HER2− breast cancer and other advanced solid tumors
Resúmenes
First-in-human phase 1a, dose-escalation study of BGB-43395 (CDK4-selective inhibitor) as monotherapy and in combination with fulvestrant or letrozole in patients with metastatic HR+/HER2− breast cancer and other advanced solid tumors
Preclinical characterization of BGB-43395, a potential best-in-class CDK4 selective inhibitor with potent pharmacodynamic and anti-tumor activity in HR+HER2- breast cancer models
Trial in progress: A first-in-human phase 1a/b, dose-escalation/expansion study of BG-68501/ETX-197 (CDK2 inhibitor) as monotherapy or in combination with fulvestrant for patients with HR+/HER2− breast cancer and other advanced solid tumors
Trial in progress: First-in-human phase 1a/1b, dose-escalation/expansion study of BGB-43395 (CDK4 selective inhibitor) as monotherapy or combination therapy in Chinese patients with metastatic HR+/HER2− breast cancer and other advanced solid tumors
Diciembre 2024
ASH (Sociedad Estadounidense de Hematología)
ASH (Sociedad Estadounidense de Hematología)
Diciembre de 2024 (San Diego, California, EE. UU.)
Presentaciones
Final analysis of a phase 1 study of zanubrutinib plus lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma
Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory Waldenstrom macroglobulinemia: results from the phase 1 CaDAnCe-101 study
Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: results from the phase 1 CaDAnCe-101 study
Sonrotoclax and zanubrutinib as frontline treatment for CLL demonstrates high MRD clearance rates with good tolerability: data from an ongoing phase 1/1b study BGB-11417-101
Pósteres
BGB-11417-203, an ongoing, phase 2 study of sonrotoclax (BGB-11417), a next-generation BCL2 inhibitor, in patients with Waldenstrom macroglobulinemia
CELESTIAL-TNCLL: an ongoing, open-label, multiregional, phase 3 study of sonrotoclax (BGB-11417) + zanubrutinib vs venetoclax + obinutuzumab for treatment-naive CLL
Comparative efficacy of zanubrutinib plus obinutuzumab versus last prior treatment in relapsed/refractory follicular lymphoma: growth modulation index analysis from ROSEWOOD study
Deep and sustained responses in patients with CLL treated with zanubrutinib or zanubrutinib + obinutuzumab in phase 1/2 AU-003 and phase 1b GA-101 studies: a report from the zanubrutinib extension study
Evaluating reasons for differences in real-world clinical outcomes among patients with relapsed/refractory mantle cell lymphoma on covalent BTK inhibitors
Impact of novel therapies on real-world clinical outcomes of patients with relapsed/refractory mantle cell lymphoma by race/ethnicity and TP53 mutation status
Long-term clinical outcomes in patients with Waldenstrom macroglobulinemia who received zanubrutinib in the phase 3 ASPEN study: a report from the zanubrutinib extension study
Long-term impact of dose interruptions of Bruton tyrosine kinase inhibitors on change in IgM levels and clinical outcomes in Waldenström macroglobulinemia
Multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in treatment-naive chronic lymphocytic leukemia: 5-year follow up, retreatment outcomes, and impact of MRD kinetics (ΔMRD400)
Patient medication preferences in follicular lymphoma in the United States: a discrete choice experiment
Preliminary efficacy and safety of the Bruton tyrosine kinsae degrader BGB-16673 in patients with relapsed or refractory indolent NHL: results from the phase 1 CaDAnCe-101 study
Prospective patient preference study for Bruton tyrosine kinase inhibitor treatment attributes and factors affecting patient shared decision-making in chronic lymphocytic leukemia and small lymphocytic lymphoma in the United States
Real-world Bruton tyrosine kinase inhibitor utilization and clinical outcomes among patients with chronic lymphocytic leukemia/small lymphocytic lymphoma
Sustained superiority of zanubrutinib vs bendamustine + rituximab in treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma: 5-year follow-up of cohort 1 from the SEQUOIA study
Zanubrutinib is well tolerated and effective in acalabrutinib-intolerant patients with B-cell malignancies
iPSC-derived CAR-γδT with novel combinatorial KO demonstrated extended longevity and profound anti-tumor efficacy without cytokine support in preclinical studies
Resúmenes
BGB-11417-203, an ongoing, phase 2 study of sonrotoclax (BGB-11417), a next-generation BCL2 inhibitor, in patients with Waldenström macroglobulinemia
BGB-16673, a selective BTK degrader, exhibits deeper inhibition of cancer cell signaling pathways and better efficacy in MCL models
CELESTIAL-TNCLL: an ongoing, open-label, multiregional, phase 3 study of sonrotoclax (BGB-11417) + zanubrutinib vs venetoclax + obinutuzumab for treatment-naive CLL
Comparative efficacy of zanubrutinib plus obinutuzumab versus last prior treatment in relapsed/refractory follicular lymphoma: growth modulation index analysis from ROSEWOOD study
Deep and sustained responses in patients with CLL treated with zanubrutinib or zanubrutinib + obinutuzumab in phase 1/2 AU-003 and phase 1b GA-101 studies: a report from the zanubrutinib extension study
Discovery of the unique GMP-Grade iPSC clones that give rise to functional, high purity, matured CD8 αβT or γδT with exponential expansion capacity
Evaluating reasons for differences in real-world (RW) clinical outcomes among patients with relapsed/refractory mantle cell lymphoma (R/R MCL) on covalent BTK inhibitors (cBTKis)
Final analysis of a phase 1 study of zanubrutinib plus lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma
Impact of novel therapies (NTs) on real-world (RW) clinical outcomes of patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL) by race/ethnicity and TP53 mutation status
Long-term clinical outcomes in patients with Waldenström macroglobulinemia (WM) who received zanubrutinib in the phase 3 ASPEN study: a report from the zanubrutinib extension study
Long-term impact of dose interruptions (DIs) of Bruton tyrosine kinase inhibitors (BTKis) on change in IgM levels and clinical outcomes in Waldenström macroglobulinemia (WM)
Multicenter Phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in treatment-naïve chronic lymphocytic leukemia: 5-year follow up, retreatment outcomes, and impact of MRD kinetics (ΔMRD400)
Patient medication preferences in follicular lymphoma (FL) in the United States (USA): a discrete choice experiment (DCE)
Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory (R/R) indolent NHL: results from the phase 1 CaDAnCe-101 study
Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory Waldenström macroglobulinemia: results from the phase 1 CaDAnCe-101 study
Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: results from the phase 1 CaDAnCe-101 study
Prospective patient preference study for Bruton tyrosine kinase inhibitor (BTKi) treatment attributes and factors affecting patient shared decision-making chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) in the United States (USA)
Real-world Bruton tyrosine kinase inhibitor (BTKi) utilization and clinical outcomes among patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)
Sonrotoclax and zanubrutinib as frontline treatment for CLL demonstrates high MRD clearance rates with good tolerability: data from an ongoing phase 1/1b study BGB-11417-101
Sustained superiority of zanubrutinib vs bendamustine + rituximab in treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (TN CLL): 5-year follow-up of cohort 1 from the SEQUOIA study
Treatment with zanubrutinib in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who were previously treated with another Bruton tyrosine kinase inhibitor in a US community oncology setting
Zanubrutinib is well tolerated and effective in acalabrutinib-intolerant patients with B-cell malignancies
iPSC-derived CAR-γδT with SOCS1/CISH/BIM/FAS combinatorial KO demonstrated extended longevity and profound anti-tumor efficacy without cytokine support in preclinical studies
Diciembre 2024
ESMO-Asia (Sociedad Europea de Oncología Médica - Asia)
ESMO-Asia (Sociedad Europea de Oncología Médica - Asia)
Diciembre de 2024 (Singapur)
Presentaciones
Asia subgroup overall survival and long-term follow-up results of the phase 2b HERIZON-BTC-01 study: Zanidatamab in previously treated human epidermal growth factor receptor 2 (HER2)-amplified biliary tract cancer (BTC)
Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT as first-line (1L) treatment for recurrent or metastatic nasopharyngeal cancer (NPC): 3-year follow-up from the RATIONALE-309 study
Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Patient reported outcomes (PRO) in the Asian subgroup of the RATIONALE-305 study
Pósteres
Characteristics and treatment patterns of patients diagnosed with nasopharyngeal carcinoma in Indonesia: A descriptive study using the national health insurance database
Direct medical costs of nasopharyngeal carcinoma in Indonesia: A healthcare payer perspective
RATIONALE-304 long-term outcomes: First-line tislelizumab (tis) + chemotherapy (chemo) vs chemo for locally advanced or metastatic nonsquamous (NSQ) NSCLC
Resúmenes
Asia subgroup overall survival and long-term follow-up results of the phase 2b HERIZON-BTC-01 study: Zanidatamab in previously treated human epidermal growth factor receptor 2 (HER2)-amplified biliary tract cancer (BTC)
Characteristics and treatment patterns of patients diagnosed with nasopharyngeal carcinoma in indonesia: A descriptive study using the national health insurance database
Direct medical costs of nasopharyngeal carcinoma in Indonesia: A healthcare payer perspective
RATIONALE-304 long-term outcomes: First-line tislelizumab (tis) + chemotherapy (chemo) vs chemo for locally advanced or metastatic nonsquamous (NSQ) NSCLC
Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT as first-line (1L) treatment for recurrent or metastatic nasopharyngeal cancer (NPC): 3-year follow-up from the RATIONALE-309 study
Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Patient reported outcomes (PRO) in the Asian subgroup of the RATIONALE-305 study
Noviembre 2024
ISPOR-EU (Sociedad Internacional de Farmacoeconomía e Investigación de Resultados)
ISPOR-EU (Sociedad Internacional de Farmacoeconomía e Investigación de Resultados)
Noviembre de 2024 (Barcelona, España)
Pósteres
Cost-effectiveness of zanubrutinib + obinutuzumab for treatment of relapsed or refractory follicular lymphoma in the United States
Economic evaluatio of tislelizumab for the treatment of second-line esophageal squamous cell carcinoma: a lifetime partition survival model
Epidemiological disparities and risk factors of esophageal cancer in Türkiye: a systematic review
Examining the impact of tislelizumab added to chemotherapy on health-related quality of life (HRQoL) outcomes in patients with advanced or metastatic esophageal squamous cell carcinoma (ESCC): the RATIONALE-306 study
Systematic literature reivew (SLR) of randomized controlled trials (RCTs) of treatments for first-line (1L) gastric cancer/gastroesophageal junction adenocarcinoma (GC/GEJ) in adult patients
Systematic literature review (SLR) of disease burden related to first-line (1L ) unresectable, locally advanced, or metastatic esophageal squamous cell carcinoma (ESCC)
The importance of assessment design when caputuring reasons for therapeutic change in cancer care
Resúmenes
Cost-effectiveness of zanubrutinib + obinutuzumab for treatment of relapsed or refractory follicular lymphoma in the United States
Economic evaluation of tislelizumab for the treatment of second-line oesophageal squamous cell carcinoma: a lifetime partition survival model
Epidemiological disparities and risk factors of esophageal cancer in Türkiye: A systematic review
Examining the impact of tislelizumab added to chemotherapy on health‑related quality of life (HRQoL) outcomes in patients with advanced or metastatic esophageal squamous cell carcinoma (ESCC): the RATIONALE-306 study
Systematic literature review (SLR) of disease burden related to first-line (1L) unresectable, locally advanced, or metastatic esophageal squamous cell carcinoma (ESCC)
Systematic literature review (SLR) of randomized controlled trials (RCTs) of treatments for first-line (1L) gastric cancer/gastroesophageal junction adenocarcinoma (GC/GEJ) in adult patients
The importance of assessment design when capturing reasons for therapeutic change in cancer care
Noviembre 2024
AIOM (Asociación Italiana de Oncología Médica)
AIOM (Asociación Italiana de Oncología Médica)
Noviembre de 2024 (Roma, Italia)
Pósteres
Concordance among three programmed death-ligand 1 (PD-L1) scoring methods and their association with clinical outcomes of tislelizumab (TIS) monotherapy in esophageal squamous cell carcinoma (ESCC)
Global, randomized, phase 3 study of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced/metastatic esophageal squamous cell carcinoma (RATIONALE-306 update): minimum 3-year survival follow-up
Pathological response to neoadjuvant tislelizumab (TIS) plus platinum-doublet (PtDb) chemotherapy (CT) in resectable stage II-IIIa NSCLC patients (pts) in the phase 3 (Ph3) RATIONALE-315 trial
Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): final analysis (FA) results of the RATIONALE-305 study
Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) + chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): health-related quality of life (HRQoL) outcomes in RATIONALE-305
Tislelizumab + chemotherapy (CT) vs placebo + CT as first-line treatment for locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma: RATIONALE-305 European/North American patient subgroup
Resúmenes
Concordance among three programmed death-ligand 1 (PD-L1) scoring methods and their association with clinical outcomes of tislelizumab (TIS) monotherapy in esophageal squamous cell carcinoma (ESCC)
Global, randomized, phase 3 study of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced/metastatic esophageal squamous cell carcinoma (RATIONALE-306 update): minimum 3-year survival follow-up
Pathological response to neoadjuvant tislelizumab (TIS) plus platinum-doublet (PtDb) chemotherapy (CT) in resectable stage II-IIIa NSCLC patients (pts) in the phase 3 (Ph3) RATIONALE-315 trial
Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): final analysis (FA) results of the RATIONALE-305 study
Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) + chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): health-related quality of life (HRQoL) outcomes in RATIONALE-305
Tislelizumab + chemotherapy (CT) vs placebo + CT as first-line treatment for locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma: RATIONALE-305 European/North American patient subgroup
Noviembre 2024
SPH (Sociedad Portuguesa de Hematología)
SPH (Sociedad Portuguesa de Hematología)
Noviembre de 2024 (Oporto, Portugal)
Noviembre 2024
SITC (Sociedad de Inmunoterapia contra el Cáncer)
SITC (Sociedad de Inmunoterapia contra el Cáncer)
Noviembre de 2024 (Houston, Texas)
Octubre 2024
BLOOD (Asamblea Científica Anual de Sangre)
BLOOD (Asamblea Científica Anual de Sangre)
Octubre de 2024 (Brisbane, Australia)
Presentaciones
Combination treatment with novel BCL2 inhibitor sonrotoclax (BGB-11417) and zanubrutinib induces high rate of complete remission in patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL)
Preliminary efficacy and safety of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients with relapsed or refractory (R/R) CLL/SLL: results from the phase 1 BGB-16673-101 study
Sonrotoclax plus dexamethasone was tolerable and demonstrated antimyeloma activity in patients with relapsed/refractory (R/R) multiple myeloma (MM) harboring t(11;14)
Pósteres
Combination treatment with sonrotoclax (BGB-11417) + zanubrutinib is well tolerated and achieves deep responses in patients with treatment-naive (TN) CLL/SLL: data from an ongoing phase 1/2 study
Monotherapy with second-generation BCL2 inhibitor sonrotoclax (BGB-11417) is well tolerated with high response rates in relapsed/refractory (R/R) marginal zone lymphoma (MZL): data from an ongoing phase 1 study
Results from the phase 1 study of the novel BCL2 inhibitor sonrotoclax (BGB-11417) in combination with zanubrutinib for relapsed/refractory (R/R) CLL/SLL show deep and durable responses
Resúmenes
Combination treatment with novel BCL2 inhibitor sonrotoclax (BGB-11417) and zanubrutinib induces high rate of complete remission in patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL)
Combination treatment with sonrotoclax (BGB-11417) + zanubrutinib is well tolerated and achieves deep responses in patients with treatment-naive (TN) CLL/SLL: data from an ongoing phase 1/2 study
Monotherapy with second-generation BCL2 inhibitor sonrotoclax (BGB-11417) is well tolerated with high response rates in relapsed/refractory (R/R) marginal zone lymphoma (MZL): data from an ongoing phase 1 study
Preliminary efficacy and safety of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients with relapsed or refractory (R/R) CLL/SLL: results from the phase 1 BGB-16673-101 study
Results from the phase 1 study of the novel BCL2 inhibitor sonrotoclax (BGB-11417) in combination with zanubrutinib for relapsed/refractory (R/R) CLL/SLL show deep and durable responses
Sonrotoclax plus dexamethasone was tolerable and demonstrated antimyeloma activity in patients with relapsed/refractory (R/R) multiple myeloma (MM) harboring t(11;14)
Octubre 2024
American Society of Nephrology Kidney Week (ASN Kidney Week)
American Society of Nephrology Kidney Week (ASN Kidney Week)
Octubre de 2024 (San Diego, California)
Octubre 2024
SIOP (Sociedad Internacional de Oncología Pediátrica)
SIOP (Sociedad Internacional de Oncología Pediátrica)
Octubre de 2024 (Honolulú, Hawái)
Octubre 2024
IWWM (Taller Internacional sobre la Macroglobulinemia de Waldenström)
IWWM (Taller Internacional sobre la Macroglobulinemia de Waldenström)
Octubre de 2024 (Praga, República Checa)
Presentaciones
BGB-11417-203, an ongoing, phase 2 study of sonrotoclax (BGB-11417), a next-generation BCL2 inhibitor, in patients with Waldenström macroglobulinemia
Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory Waldenström macroglobulinemia: Results from the phase 1 CaDAnCe-101 study
Safety and efficacy results of a phase 1 study of the novel BCL2 inhibitor sonrotoclax (BGB-11417) for relapsed/refractory Waldenström macroglobulinemia
Zanubrutinib is well tolerated and effective in ibrutinib/acalabrutinib-intolerant patients with Waldenström macroglobulinemia
Pósteres
Improving the quality of active monitoring in Waldenström macroglobulinemia: Results of a UK-wide patient-centered experience survey and proposed standard of care for active monitoring from a UK-wide patient-expert collaboration
Peripheral neuropathy in phase 3 ASPEN study of Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemia
Resúmenes
BGB-11417-203, an ongoing, phase 2 study of sonrotoclax (BGB-11417), a next-generation BCL2 inhibitor, in patients with Waldenström macroglobulinemia
Improving the quality of active monitoring in Waldenström macroglobulinemia: Results of a UK-wide patient-centered experience survey and proposed standard of care for active monitoring from a UK-wide patient-expert collaboration
Peripheral neuropathy in phase 3 ASPEN study of Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemia
Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory Waldenström macroglobulinemia: Results from the phase 1 CaDAnCe-101 study
Safety and efficacy results of a phase 1 study of the novel BCL2 inhibitor sonrotoclax (BGB-11417) for relapsed/refractory Waldenström macroglobulinemia
Octubre 2024
DGHO (Sociedades Alemana, Austríaca y Suiza de Hematología y Oncología)
DGHO (Sociedades Alemana, Austríaca y Suiza de Hematología y Oncología)
Octubre de 2024 (Basilea, Suiza)
Presentaciones
Combination of zanubrutinib (zanu) + venetoclax (ven) for treatment-naive (TN) CLL/SLL with del(17p) and/or TP53: preliminary results from SEQUOIA arm D
Combination treatment (tx) with novel BCL2 inhibitor sonrotoclax (sonro; BGB-11417) and zanubrutinib (zanu) induces high rate of complete remission in patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL)
Preliminary efficacy and safety of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients (pts) with relapsed or refractory (R/R) indolent NHL: results from the phase 1 BGB-16673-101 study
Preliminary safety and antileukemic activity of sonrotoclax (BGB-11417), a potent and selective BCL2 Inhibitor, in treatment-naive (TN) patients with acute myeloid leukemia (AML)
Preliminary safety and antileukemic activity of sonrotoclax (BGB-11417), a potent and selective BCL2 inhibitor, in patients (pts) with relapsed/refractory (R/R) acute myeloid leukemia (AML)
Sonrotoclax (sonro; BGB-11417) + dexamethasone (dex) is tolerable and demonstrates antimyeloma activity in patients with relapsed/refractory (R/R) multiple myeloma (MM) harboring t(11;14)
Pósteres
2 years of zanubrutinib in Germany: a retrospective cohort study
Outcomes ≥1 year after transitioning from treatment with ibrutinib (ibru) in the ASPEN study to zanubrutinib (zanu)
Preliminary efficacy and safety of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients (pts) with relapsed or refractory (R/R) CLL/SLL: results from the phase 1 BGB-16673-101 study
Results from the phase 1 study of the novel BCL2 inhibitor sonrotoclax (sonro; BGB-11417) in combination with zanubrutinib (zanu) for relapsed/refractory (R/R) CLL/SLL show deep and durable responses
Safety and efficacy results of a phase 1 study of the novel BCL2 inhibitor sonrotoclax (sonro; BGB-11417) for relapsed/refractory (R/R) Waldenström macroglobulinemia (WM)
Resúmenes
2 years of zanubrutinib in Germany: a retrospective cohort study
Combination of zanubrutinib (zanu) + venetoclax (ven) for treatment-naive (TN) CLL/SLL with del(17p) and/or TP53: preliminary results from SEQUOIA arm D
Combination treatment (tx) with novel BCL2 inhibitor sonrotoclax (sonro; BGB-11417) and zanubrutinib (zanu) induces high rate of complete remission in patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL)
Global, randomized, phase III study of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced/metastatic esophageal squamous cell carcinoma (RATIONALE-306 update): minimum 3-year survival follow-up
Outcomes ≥1 year after transitioning from treatment with ibrutinib (ibru) in the ASPEN study to zanubrutinib (zanu)
Preliminary efficacy and safety of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients (pts) with relapsed or refractory (R/R) CLL/SLL: results from the phase 1 BGB-16673-101 study
Preliminary efficacy and safety of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients (pts) with relapsed or refractory (R/R) indolent NHL: results from the phase 1 BGB-16673-101 study
Preliminary safety and antileukemic activity of sonrotoclax (BGB-11417), a potent and selective BCL2 Inhibitor, in treatment-naive (TN) patients with acute myeloid leukemia (AML)
Preliminary safety and antileukemic activity of sonrotoclax (BGB-11417), a potent and selective BCL2 inhibitor, in patients (pts) with relapsed/refractory (R/R) acute myeloid leukemia (AML)
Results from the phase 1 study of the novel BCL2 inhibitor sonrotoclax (sonro; BGB-11417) in combination with zanubrutinib (zanu) for relapsed/refractory (R/R) CLL/SLL show deep and durable responses
Safety and efficacy results of a phase 1 study of the novel BCL2 inhibitor sonrotoclax (sonro; BGB-11417) for relapsed/refractory (R/R) Waldenström macroglobulinemia (WM)
Sonrotoclax (sonro; BGB-11417) + dexamethasone (dex) is tolerable and demonstrates antimyeloma activity in patients with relapsed/refractory (R/R) multiple myeloma (MM) harboring t(11;14)
Septiembre 2024
ERIC CLL (Iniciativa de Investigación Europea sobre la LLC)
ERIC CLL (Iniciativa de Investigación Europea sobre la LLC)
Septiembre 2024 (Barcelona, España)
Pósteres
Combination treatment with sonrotoclax (BGB-11417), a second-generation BCL2 inhibitor, and zanubrutinib, a Bruton tyrosine kinase (BTK) inhibitor, is well tolerated and achieves deep responses in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (TN-CLL/SLL): data from an ongoing phase 1/2 study
Preliminary efficacy and safety of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients with relapsed or refractory (R/R) CLL/SLL: Results from the phase 1 BGB-16673-101 study
Results from the phase 1 study of the novel BCL2 inhibitor sonrotoclax in combination with zanubrutinib for relapsed/refractory (R/R) CLL/SLL show deep and durable response
Resúmenes
Combination treatment with sonrotoclax (BGB-11417), a second-generation BCL2 inhibitor, and zanubrutinib, a Bruton tyrosine kinase (BTK) inhibitor, is well tolerated and achieves deep responses in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (TN-CLL/SLL): data from an ongoing phase 1/2 study
Preliminary efficacy and safety of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients with relapsed or refractory (R/R) CLL/SLL: Results from the phase 1 BGB-16673-101 study
Results from the phase 1 study of the novel BCL2 inhibitor sonrotoclax in combination with zanubrutinib for relapsed/refractory (R/R) CLL/SLL show deep and durable response
Septiembre 2024
KSMO (Sociedad Coreana de Oncología Médica)
KSMO (Sociedad Coreana de Oncología Médica)
Septiembre 2024 (Seúl, Corea del Sur)
Septiembre 2024
Reunión de la IMS (Sociedad Internacional de Mieloma)
Reunión de la IMS (Sociedad Internacional de Mieloma)
Septiembre de 2024 (Río de Janeiro, Brasil)
Septiembre 2024
CSCO (Sociedad China de Oncología Clínica)
CSCO (Sociedad China de Oncología Clínica)
Septiembre de 2024 (Xiamen, China)
Presentaciones
A phase 2 study of sitravatinib in combination with tislelizumab versus chemotherapy in patients with locally advanced unresectable or metastatic esophageal squamous cell carcinoma that progressed on or after anti–PD-1/anti–PD-L1 antibody therapy
China subgroup results of the phase (Ph) 2b HERIZON-BTC-01 study: Zanidatamab in previously-treated HER2-amplified biliary tract cancer (BTC)
Combination treatment with novel BCL-2 inhibitor sonrotoclax (BGB-11417) and zanubrutinib induces high rate of complete remission for patients with relapsed/refractory mantle cell lymphoma
Extended follow-up of ALPINE randomized phase 3 study confirms sustained superior progression-free survival of zanubrutinib versus ibrutinib for treatment of relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma
Impact of first-line treatment with tislelizumab on health-related quality of life in Chinese patients with unresectable hepatocellular carcinoma
Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory indolent non-Hodgkin lymphoma: results from the phase 1 BGB-16673-101 study
Pósteres
Preliminary safety and antileukemic activity of sonrotoclax (BGB-11417), a potent and selective BCL2 inhibitor, in patients with relapsed/refractory acute myeloid leukemia
Safety and efficacy results of a phase 1 study of the novel BCL2 inhibitor sonrotoclax (BGB-11417) for relapsed/refractory Waldenström macroglobulinemia
Sonrotoclax plus dexamethasone is tolerable and demonstrates antimyeloma activity in patients with relapsed/refractory (R/R) multiple myeloma harboring t(11;14)
Zanidatamab, a HER2-targeted bispecific antibody, in combination with docetaxel as first-line therapy for patients with advanced HER2-positive breast cancer: Updated results from a Phase Ib/II study
Resúmenes
A phase 1 study with the novel B-cell lymphoma 2 (Bcl-2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with CLL/SLL: Preliminary data
A phase 1 study with the novel B-cell lymphoma 2 (Bcl-2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with non-Hodgkin lymphoma (NHL) or Waldenström macroglobulinemia (WM): Preliminary data
A phase 2 study of sitravatinib in combination with tislelizumab versus chemotherapy in patients with locally advanced unresectable or metastatic esophageal squamous cell carcinoma that progressed on or after anti–PD-1/anti–PD-L1 antibody therapy
CELESTIAL-TNCLL: An ongoing, open-label, multiregional, phase 3 study of sonrotoclax (BGB-11417) + zanubrutinib vs venetoclax + obinutuzumab for treatment-naive CLL
China subgroup results of the phase (Ph) 2b HERIZON-BTC-01 study: Zanidatamab in previously-treated HER2-amplified biliary tract cancer (BTC)
Combination treatment with novel BCL-2 inhibitor sonrotoclax (BGB-11417) and zanubrutinib induces high rate of complete remission for patients with relapsed/refractory mantle cell lymphoma
Efficacy and safety of tislelizumab + chemotherapy vs placebo + chemotherapy in HER2-negative advanced or metastatic gastric or gastroesophageal junction adenocarcinoma: RATIONALE-305 study Chinese subgroup analysis
Extended follow-up of ALPINE randomized phase 3 study confirms sustained superior progression-free survival of zanubrutinib versus ibrutinib for treatment of relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma
First interim analysis of a phase 1 study of zanubrutinib plus lenalidomide in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL)
Impact of first-line treatment with tislelizumab on health-related quality of life in Chinese patients with unresectable hepatocellular carcinoma
Improved efficacy and safety of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia in China: a subgroup of ALPINE
Long-term efficacy and safety of zanubrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL): final analysis of the MAGNOLIA (BGB-3111-214) trial
MAHOGANY: A phase 3 trial of zanubrutinib plus anti-CD20 antibodies vs lenalidomide plus rituximab in patients with relapsed or refractory follicular or marginal zone lymphoma
Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory CLL/SLL: results from the phase 1 BGB-16673-101 study
Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory indolent non-Hodgkin lymphoma: results from the phase 1 BGB-16673-101 study
Preliminary safety and antileukemic activity of sonrotoclax (BGB-11417), a potent and selective BCL2 inhibitor, in patients with relapsed/refractory acute myeloid leukemia
Preliminary safety and antileukemic activity of sonrotoclax (BGB-11417), a potent and selective BCL2 inhibitor, in treatment-naive patients with acute myeloid leukemia
Results from the phase 1 study of the novel BCL2 inhibitor sonrotoclax in combination with zanubrutinib for relapsed/refractory CLL/SLL show deep and durable responses
Safety and efficacy results of a phase 1 study of the novel BCL2 inhibitor sonrotoclax (BGB-11417) for relapsed/refractory Waldenström macroglobulinemia
Sonrotoclax plus dexamethasone is tolerable and demonstrates antimyeloma activity in patients with relapsed/refractory (R/R) multiple myeloma harboring t(11;14)
Zanidatamab, a HER2-targeted bispecific antibody, in combination with docetaxel as first-line therapy for patients with advanced HER2-positive breast cancer: Updated results from a Phase Ib/II study
Zanubrutinib demonstrates superior progression-free survival (PFS) compared with ibrutinib for treatment of relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): final analysis of ALPINE randomized phase 3 study
Zanubrutinib plus obinutuzumab vs obinutuzumab in patients with relapsed/refractory follicular lymphoma: updated analysis of the ROSEWOOD study
Zanubrutinib vs ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): impact on health-related quality of life (HRQOL)
Septiembre 2024
SIE (Sociedad Italiana de Hematología)
SIE (Sociedad Italiana de Hematología)
Septiembre de 2024 (Milán, Italia)
Presentaciones
Combination of zanubrutinib (zanu) + venetoclax (ven) in patients with treatment-naive (TN) CLL/SLL with del(17p) and/or TP53: Preliminary results from SEQUOIA arm D
Combination treatment with sonrotoclax (sonro; BGB-11417) + zanubrutinib (zanu) is well tolerated and achieves deep responses in patients with treatment-naive CLL/SLL: Data from an ongoing phase 1/2 study
Results from the phase 1 study of the novel BCL2 inhibitor sonrotoclax (sonro; BGB-11417) in combination with zanubrutinib (zanu) for relapsed/refractory (R/R) CLL/SLL show deep and durable responses
Pósteres
CELESTIAL-TNCLL: An ongoing, open-label, multiregional, phase 3 study of sonrotoclax (BGB-11417) + zanubrutinib vs venetoclax + obinutuzumab in treatment-naive CLL
Intrapatient comparative analysis of zanubrutinib plus obinutuzumab efficacy in relapsed/refractory (R/R) follicular lymphoma (FL) using the growth modulation index (GMI)
Monotherapy with second-generation BCL2 inhibitor sonrotoclax (BGB-11417) is well tolerated, with high response rates in relapsed/refractory (R/R) marginal zone lymphoma (MZL): Data from an ongoing phase 1 study
Outcomes ≥1 year after transitioning from treatment with ibrutinib (ibru) in the ASPEN study to zanubrutinib (zanu)
Preliminary efficacy and safety of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients (pts) with relapsed or refractory (R/R) CLL/SLL: Results from the phase 1 BGB-16673-101 study
Preliminary efficacy and safety of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients (pts) with relapsed or refractory (R/R) indolent non-Hodgkin lymphoma (NHL): Results from the phase 1 BGB-16673-101 study
Risk of hypertension in patients with CLL/SLL who participated in the ALPINE study: A post hoc analysis
Resúmenes
CELESTIAL-TNCLL: An ongoing, open-label, multiregional, phase 3 study of sonrotoclax (BGB-11417) + zanubrutinib vs venetoclax + obinutuzumab in treatment-naive CLL
Combination of zanubrutinib (zanu) + venetoclax (ven) in patients with treatment-naive (TN) CLL/SLL with del(17p) and/or TP53: Preliminary results from SEQUOIA arm D
Combination treatment with sonrotoclax (sonro; BGB-11417) + zanubrutinib (zanu) is well tolerated and achieves deep responses in patients with treatment-naive CLL/SLL: Data from an ongoing phase 1/2 study
Intrapatient comparative analysis of zanubrutinib plus obinutuzumab efficacy in relapsed/refractory (R/R) follicular lymphoma (FL) using the growth modulation index (GMI)
Monotherapy with second-generation BCL2 inhibitor sonrotoclax (BGB-11417) is well tolerated, with high response rates in relapsed/refractory (R/R) marginal zone lymphoma (MZL): Data from an ongoing phase 1 study
Outcomes ≥1 year after transitioning from treatment with ibrutinib (ibru) in the ASPEN study to zanubrutinib (zanu)
Preliminary efficacy and safety of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients (pts) with relapsed or refractory (R/R) CLL/SLL: Results from the phase 1 BGB-16673-101 study
Preliminary efficacy and safety of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients (pts) with relapsed or refractory (R/R) indolent non-Hodgkin lymphoma (NHL): Results from the phase 1 BGB-16673-101 study
Results from the phase 1 study of the novel BCL2 inhibitor sonrotoclax (sonro; BGB-11417) in combination with zanubrutinib (zanu) for relapsed/refractory (R/R) CLL/SLL show deep and durable responses
Risk of hypertension in patients with CLL/SLL who participated in the ALPINE study: A post hoc analysis
Septiembre 2024
ESMO (Sociedad Europea de Oncología Médica)
ESMO (Sociedad Europea de Oncología Médica)
Septiembre 2024 (Barcelona, España)
Pósteres
Comparative efficacy and safety of tislelizumab versus anti-PD-1 treatments in second line esophageal squamous cell carcinoma: simulated treatment comparisons
Neoadjuvant tislelizumab (TIS) plus chemotherapy (CT) with adjuvant TIS vs. neoadjuvant placebo (PBO) plus CT with adjuvant PBO in resectable non-small cell lung cancer (NSCLC): patient-reported outcomes (PRO) in the RATIONALE-315 trial
RATIONALE-307 long-term outcomes: first-line tislelizumab (TIS) plus chemotherapy (chemo) vs chemo alone for advanced squamous (sq) NSCLC
Real-world overall survival (os) in recurrent/metastatic nasopharyngeal carcinoma (R/M NPC) in asia:a literature review
Recurrent patient-reported outcome (PRO)-based symptomatic deterioration predicts progression-free survival (PFS): Results from RATIONALE-305
Tislelizumab (TIS) + chemotherapy (CT) vs placebo (PBO) + CT in HER2-negative advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GC/GEJC): RATIONALE-305 study minimum 3-year survival follow-up
Resúmenes
Comparative efficacy and safety of tislelizumab versus anti-PD-1 treatments in second line esophageal squamous cell carcinoma: simulated treatment comparisons
Neoadjuvant tislelizumab (TIS) plus chemotherapy (CT) with adjuvant TIS vs. neoadjuvant placebo (PBO) plus CT with adjuvant PBO in resectable non-small cell lung cancer (NSCLC): patient-reported outcomes (PRO) in the RATIONALE-315 trial
RATIONALE-307 long-term outcomes: first-line tislelizumab (TIS) plus chemotherapy (chemo) vs chemo alone for advanced squamous (sq) NSCLC
RATIONALE-315: event-free survival (EFS) and overall survival (OS) of neoadjuvant tislelizumab (TIS) plus chemotherapy (CT) with adjuvant TIS in resectable non-small cell lung cancer (NSCLC)
Real-world overall survival (os) in recurrent/metastatic nasopharyngeal carcinoma (R/M NPC) in asia:a literature review
Recurrent patient-reported outcome (PRO)-based symptomatic deterioration predicts progression-free survival (PFS): Results from RATIONALE-305
Tislelizumab (TIS) + chemotherapy (CT) vs placebo (PBO) + CT in HER2-negative advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GC/GEJC): RATIONALE-305 study minimum 3-year survival follow-up
Septiembre 2024
WCLC (World Conference on Lung Cancer)
WCLC (World Conference on Lung Cancer)
Septiembre de 2024 (San Diego, California)
Agosto 2024
Evento anual de APGCS (Cumbre de Gastroenterología Oncológica de Asia-Pacífico)
Evento anual de APGCS (Cumbre de Gastroenterología Oncológica de Asia-Pacífico)
Agosto de 2024 (Singapur, República de Singapur)
Pósteres
First-line tislelizumab plus chemotherapy in gastric/gastroesophageal junction cancer: RATIONALE-305 Asian subgroup
Tislelizumab (TIS) plus chemotherapy (chemo) vs placebo (PBO) plus chemo as first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Health-related quality of life outcomes in the RATIONALE-305 study
Resúmenes
First-line tislelizumab plus chemotherapy in gastric/gastroesophageal junction cancer: RATIONALE-305 Asian subgroup
Tislelizumab (TIS) plus chemotherapy (chemo) vs placebo (PBO) plus chemo as first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Health-related quality of life outcomes in the RATIONALE-305 study
Julio 2024
PPLC (Pan Pacific Lymphoma Conference)
PPLC (Pan Pacific Lymphoma Conference)
Julio de 2024 (Lahaina, Hawái)
Pósteres
Real-world Bruton tyrosine kinase inhibitor treatment patterns and outcomes among patients with chronic lymphocytic leukemia or small lymphocytic lymphoma in US community oncology practices
Real-world comparative effectiveness of covalent Bruton tyrosine kinase inhibitors (cBTKi) among patients with relapsed/refractory mantle cell lymphoma (R/R MCL)
Recent patterns of care with BTK inhibitors and distribution of social determinants of health among patients with CLL/SLL in the US community setting
Resúmenes
Real-world Bruton tyrosine kinase inhibitor treatment patterns and outcomes among patients with chronic lymphocytic leukemia or small lymphocytic lymphoma in US community oncology practices
Real-world comparative effectiveness of covalent Bruton tyrosine kinase inhibitors (cBTKi) among patients with relapsed/refractory mantle cell lymphoma (R/R MCL)
Recent patterns of care with BTK inhibitors and distribution of social determinants of health among patients with CLL/SLL in the US community setting
Junio 2024
ESMO-GI (Congreso sobre Cánceres Gastrointestinales de la Sociedad Europea de Oncología Médica)
ESMO-GI (Congreso sobre Cánceres Gastrointestinales de la Sociedad Europea de Oncología Médica)
Junio de 2024 (Múnich, Alemania)
Presentaciones
Tislelizumab (TIS) + chemotherapy (CT) vs placebo (PBO) + CT in advanced or metastatic esophageal squamous cell carcinoma (ESCC): PD-L1 biomarker analysis from RATIONALE-306
Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT in HER2-negative advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma (GC/GEJC): PD-L1 biomarker analysis from RATIONALE-305
Resúmenes
Tislelizumab (TIS) + chemotherapy (CT) vs placebo (PBO) + CT in advanced or metastatic esophageal squamous cell carcinoma (ESCC): PD-L1 biomarker analysis from RATIONALE-306
Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT in HER2-negative advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma (GC/GEJC): PD-L1 biomarker analysis from RATIONALE-305
Junio 2024
EHA (Asociación Europea de Hematología)
EHA (Asociación Europea de Hematología)
Junio de 2024 (Madrid, España)
Presentaciones
Combination of zanubrutinib + venetoclax for treatment-naive (TN) CLL/SLL with del(17p) and/or TP53: preliminary results from SEQUOIA arm D
Preliminary efficacy and safety of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients with relapsed or refractory (R/R) CLL/SLL: Results from the phase 1 BGB-16673-101 study
Results from the phase 1 study of the novel BCL2 inhibitor sonrotoclax (sonro) in combination with zanubrutinib (zanu) for relapsed/refractory (R/R) CLL/SLL show deep and durable responses
Zanubrutinib vs. acalabrutinib in B-cell malignancies: an adverse event-based economic analysis
Pósteres
Combination treatment with novel BCL-2 inhibitor sonrotoclax (BGB-11417) and zanubrutinib induces high rate of complete remission for patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL)
Comparative efficacy of Bruton tyrosine kinase inhibitors in the treatment of relapsed/refractory chronic lymphocytic leukemia: a network meta-analysis
Efficacy and safety of zanubrutinib vs. venetoclax+ibrutinib in the treatment-naïve (TN) chronic lymphocytic leukemia (CLL): a matching-adjusted indirect comparison (MAIC)
Efficacy of zanubrutinib versus acalabrutinib in the treatment of relapsed or refractory chronic lymphocytic leukemia (R/R CLL): a matching-adjusted indirect comparison (MAIC)
Indirect comparison of efficacy of zanubrutinib versus acalabrutinib in the treatment of relapsed/refractory mantle cell lymphoma
Intrapatient comparative analysis of zanubrutinib plus obinutuzumab efficacy in relapsed/refractory follicular lymphoma using the growth modulation index
Matching-adjusted indirect comparison (MAIC) of zanubrutinib versus real-world chemoimmunotherapy (CIT) or chemotherapy (Chemo) in relapsed/refractory marginal zone lymphoma (R/R MZL)
Patient-reported outcome (PRO)–based recurrent symptomatic deterioration predicts disease progression: results from the ALPINE trial
Preliminary efficacy and safety of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients with relapsed or refractory (R/R) indolent NHL: results from the phase 1 BGB-16673-101 study
Preliminary safety and antileukemic activity of sonrotoclax (BGB-11417), a potent and selective BCL2 inhibitor, in patients with relapsed/refractory acute myeloid leukemia
Preliminary safety and antileukemic activity of sonrotoclax (BGB-11417), a potent and selective BCL2 inhibitor, in treatment-naive patients with acute myeloid leukemia
Real-world Bruton tyrosine kinase inhibitor treatment patterns and outcomes among patients with chronic lymphocytic leukemia or small lymphocytic lymphoma in US community oncology practices
Real-world adherence and healthcare resource utilization of Bruton tyrosine kinase inhibitors (BTKi) in mantle cell lymphoma
Real-world comparative effectiveness of covalent Bruton tyrosine kinase inhibitors (cBTKi) among patients with relapsed/refractory mantle cell lymphoma (R/R MCL)
Real-world evaluation of treatment patern, time to next treatment, healthcare resource utilization, and cost of care in follicular lymphoma
Real-world treatment switching and sequencing to next line of therapy of zanubrutinib, acalabrutinib, and ibrutinib in CLL/SLL
Risk of hypertension in patients with CLL/SLL who participated in ALPINE: a post hoc analysis
Risk of new-onset hypertension in newly diagnosed chronic lymphocytic leukemia patients treated with Bruton tyrosine kinase inhibitors: a real-world study using the Symphony Health Solutions database
Safety and efficacy results of a phase 1 study of the novel BCL2 inhibitor sonrotoclax (BGB-11417) for relapsed/refractory Waldenström's macroglobulinemia
Sonrotoclax plus dexamethasone is tolerable and demonstrates antimyeloma activity in patients with relapsed/refractory (R/R) multiple myeloma harboring t(11;14)
Zanubrutinib vs other Bruton’s tyrosine kinase inhibitors in relapsed/refractory chronic lymphocytic leukemia: a multilevel network meta-regression
Resúmenes
BGB-11417-203, an ongoing, phase 2 study of sonrotoclax (BGB-11417), a next-generation BCL2 inhibitor, in patients with Waldenström macroglobulinemia
CELESTIAL-TNCLL: an ongoing, open-label, multiregional, phase 3 study of sonrotoclax (BGB-11417) + zanubrutinib vs venetoclax + obinutuzumab for treatment-naive (TN) CLL
Combination of zanubrutinib + venetoclax for treatment-naive (TN) CLL/SLL with del(17p) and/or TP53: preliminary results from SEQUOIA arm D
Combination treatment with novel BCL-2 inhibitor sonrotoclax (BGB-11417) and zanubrutinib induces high rate of complete remission for patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL)
Comparative efficacy of Bruton tyrosine kinase inhibitors in the treatment of relapsed/refractory chronic lymphocytic leukemia: a network meta-analysis
Efficacy and safety of zanubrutinib vs. venetoclax+ibrutinib in the treatment-naïve (TN) chronic lymphocytic leukemia (CLL): a matching-adjusted indirect comparison (MAIC)
Efficacy of zanubrutinib versus acalabrutinib in the treatment of relapsed or refractory chronic lymphocytic leukemia (R/R CLL): a matching-adjusted indirect comparison (MAIC)
Indirect comparison of efficacy of zanubrutinib versus acalabrutinib in the treatment of relapsed/refractory mantle cell lymphoma
Intrapatient comparative analysis of zanubrutinib plus obinutuzumab efficacy in relapsed/refractory follicular lymphoma using the growth modulation index
Matching-adjusted indirect comparison (MAIC) of zanubrutinib versus real-world chemoimmunotherapy (CIT) or chemotherapy (Chemo) in relapsed/refractory marginal zone lymphoma (R/R MZL)
Patient-reported outcome (PRO)–based recurrent symptomatic deterioration predicts disease progression: results from the ALPINE trial
Preliminary efficacy and safety of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients with relapsed or refractory (R/R) CLL/SLL: Results from the phase 1 BGB-16673-101 study
Preliminary efficacy and safety of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients with relapsed or refractory (R/R) indolent NHL: results from the phase 1 BGB-16673-101 study
Preliminary safety and antileukemic activity of sonrotoclax (BGB-11417), a potent and selective BCL2 inhibitor, in patients with relapsed/refractory acute myeloid leukemia
Preliminary safety and antileukemic activity of sonrotoclax (BGB-11417), a potent and selective BCL2 inhibitor, in treatment-naive patients with acute myeloid leukemia
Real-world Bruton tyrosine kinase inhibitor treatment patterns and outcomes among patients with chronic lymphocytic leukemia or small lymphocytic lymphoma in US community oncology practices
Real-world adherence and healthcare resource utilization of Bruton tyrosine kinase inhibitors (BTKi) in mantle cell lymphoma
Real-world comparative effectiveness of covalent Bruton tyrosine kinase inhibitors (cBTKi) among patients with relapsed/refractory mantle cell lymphoma (R/R MCL)
Real-world evaluation of treatment patern, time to next treatment, healthcare resource utilization, and cost of care in follicular lymphoma
Real-world treatment switching and sequencing to next line of therapy of zanubrutinib, acalabrutinib, and ibrutinib in CLL/SLL
Recent patterns of care with btk inhibitors and distribution of social determinants of health among patients with cll/sll in the us community setting
Results from the phase 1 study of the novel BCL2 inhibitor sonrotoclax (sonro) in combination with zanubrutinib (zanu) for relapsed/refractory (R/R) CLL/SLL show deep and durable responses
Risk of hypertension in patients with CLL/SLL who participated in ALPINE: a post hoc analysis
Risk of new-onset hypertension in newly diagnosed chronic lymphocytic leukemia patients treated with Bruton tyrosine kinase inhibitors: a real-world study using the Symphony Health Solutions database
Safety and efficacy results of a phase 1 study of the novel BCL2 inhibitor sonrotoclax (BGB-11417) for relapsed/refractory Waldenström's macroglobulinemia
Sonrotoclax plus dexamethasone is tolerable and demonstrates antimyeloma activity in patients with relapsed/refractory (R/R) multiple myeloma harboring t(11;14)
Zanubrutinib vs other Bruton’s tyrosine kinase inhibitors in relapsed/refractory chronic lymphocytic leukemia: a multilevel network meta-regression
Zanubrutinib vs. acalabrutinib in B-cell malignancies: an adverse event-based economic analysis
Mayo 2024
ASCO (Sociedad Estadounidense de Oncología Clínica)
ASCO (Sociedad Estadounidense de Oncología Clínica)
Mayo de 2024 (Chicago, Illinois, EE. UU.)
Pósteres
A first in human phase 1a dose escalation study of BGB 15025 (HPK1 inhibitor) as monotherapy and in combination with tislelizumab (TIS; anti PD 1 antibody) in patients (pts) with advanced solid tumors
BGB-11417-203, an ongoing, phase 2 study of sonrotoclax (BGB-11417), a next-generation BCL2 inhibitor, in patients with Waldenström macroglobulinemia
BGB-A317-212: a multicenter, open-label, phase II study to evaluate the efficacy and safety of tislelizumab in combination with lenvatinib in patients with selected solid tumors
CELESTIAL-TNCLL: an ongoing, open-label, multiregional, phase 3 study of sonrotoclax (BGB-11417) + zanubrutinib vs venetoclax + obinutuzumab for treatment-naïve (TN) CLL
Clinical and financial burden of mental health (MH) conditions in patients (pts) with low-grade non-Hodgkin lymphoma (LG-NHL)
Comparative efficacy of Bruton tyrosine kinase inhibitors in the treatment of relapsed/refractory chronic lymphocytic leukemia: a network meta-analysis (NMA)
Global, randomized, phase III study of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced/metastatic esophageal squamous cell carcinoma (RATIONALE-306 update): minimum 3-year survival follow-up
Preoperative (neoadjuvant) therapy with tislelizumab for locally advanced colorectal cancer with high microsatellite instability or deficient mismatch repair: an open-label, single-arm, multicenter phase II study
Real-world treatment patterns and outcomes of zanubrutinib in chronic lymphocytic leukemia and small lymphocytic leukemia (CLL/SLL)
Tislelizumab first-line (1L) gastric/gastroesophageal junction cancer (G/GEJ) treatment efficacy on patient-reported outcome (PRO)-based symptom endpoints adjusting for informative missing data bias: results from RATIONALE 305
Resúmenes
A first in human phase 1a dose escalation study of BGB-15025 (HPK1 inhibitor) as monotherapy and in combination with tislelizumab (TIS; anti PD 1 antibody) in patients (pts) with advanced solid tumors
BGB-11417-203: an ongoing, phase 2 study of sonrotoclax (BGB-11417), a next-generation BCL2 inhibitor, in patients with Waldenström macroglobulinemia
BGB-A317-212: a multicenter, open-label, phase II study to evaluate the efficacy and safety of tislelizumab in combination with lenvatinib in patients with selected solid tumors
CELESTIAL-TNCLL: an ongoing, open-label, multiregional, phase 3 study of sonrotoclax (BGB-11417) + zanubrutinib vs venetoclax + obinutuzumab for treatment-naïve (TN) CLL
Clinical and financial burden of mental health (MH) conditions in patients (pts) with low-grade non-Hodgkin lymphoma (LG-NHL)
Comparative efficacy of Bruton tyrosine kinase inhibitors in the treatment of relapsed/refractory chronic lymphocytic leukemia: a network meta-analysis (NMA)
Comparison of zanubrutinib (zanu) and acalabrutinib (acala) in B-cell malignancies: an adverse event (AE)-based analysis
Global, randomized, phase III study of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced/metastatic esophageal squamous cell carcinoma (RATIONALE-306 update): minimum 3-year survival follow-up
Long-term pooled safety analysis of tislelizumab as monotherapy or in combination with chemotherapy in patients with advanced cancers
Preoperative (neoadjuvant) therapy with tislelizumab for locally advanced colorectal cancer with high microsatellite instability or deficient mismatch repair: An open-label, single-arm, multicenter phase II study
Real-world Bruton tyrosine kinase inhibitor (BTKi) treatment patterns and outcomes among patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) in US community oncology practices
Real-world adherence and healthcare resource utilization of Bruton tyrosine kinase inhibitors (BTKi) in mantle cell lymphoma
Real-world evaluation of treatment pattern, time to next treatment (TTNT), healthcare resource utilization (HCRU), and cost of care in follicular lymphoma (FL)
Real-world treatment patterns and outcomes of zanubrutinib in chronic lymphocytic leukemia and small lymphocytic leukemia (CLL/SLL)
Real-world treatment switching and sequencing to next line of therapy of zanubrutinib, acalabrutinib, and ibrutinib in CLL/SLL
Risk of hypertension in patients with CLL/SLL who participated in ALPINE: a post hoc analysis
Risk of new-onset hypertension in newly diagnosed chronic lymphocytic leukemia (CLL) patients (pts) treated with Bruton tyrosine kinase inhibitors (BTKis): a real-world data study using the Symphony Health Solutions database
Tislelizumab first-line (1L) gastric/gastroesophageal junction cancer (G/GEJ) treatment efficacy on patient-reported outcome (PRO)-based symptom endpoints adjusting for informative missing data bias: results from RATIONALE 305
Mayo 2024
ISPOR (Sociedad Internacional de Farmacoeconomía e Investigación de Resultados)
ISPOR (Sociedad Internacional de Farmacoeconomía e Investigación de Resultados)
Mayo de 2024 (Atlanta, Georgia)
Pósteres
Budget impact analysis of zanubrutinib + obinutuzumab for the treatment of relapsed or refractory follicular lymphoma in the United States
Clinical outcomes of first-line (1L) treatments (txs) in locally advanced or metastatic non-small cell lung cancer (aNSCLC): a systematic literature review (SLR)
Clinical outcomes of second-line (2L) treatments (txs) in locally advanced or metastatic esophageal squamous cell carcinoma (ESCC): a systematic literature review (SLR)
Clinical outcomes of second-line and beyond (2L+) treatments (txs) in locally advanced or metastatic non-small cell lung cancer (aNSCLC): a systematic literature review (SLR)
Outcomes with novel therapies for relapsed or refractory follicular lymphoma: a targeted literature review
Systematic literature review (SLR) of randomized controlled trials (RCTs) of immuno-oncology (IO) for first-line (1L) esophageal squamous cell carcinoma (ESCC) in adults patients
Systematic literature review (SLR) of randomized controlled trials (RCTs) of immuno-oncology (IO) for first-line (1L) esophageal squamous cell carcinoma (ESCC) in adults patients (Supplemental)
Targeted literature review of cost-effectiveness models in relapsed/refractory follicular lymphoma
Resúmenes
Budget impact analysis of zanubrutinib + obinutuzumab for the treatment of relapsed or refractory follicular lymphoma in the United States
Clinical outcomes of first-line (1L) treatments (txs) in locally advanced or metastatic non-small cell lung cancer (aNSCLC): a systematic literature review (SLR)
Clinical outcomes of second-line (2L) treatments (txs) in locally advanced or metastatic esophageal squamous cell carcinoma (ESCC): a systematic literature review (SLR)
Clinical outcomes of second-line and beyond (2L+) treatments (txs) in locally advanced or metastatic non-small cell lung cancer (aNSCLC): a systematic literature review (SLR)
Outcomes with novel therapies for relapsed or refractory follicular lymphoma: a targeted literature review
Systematic literature review (SLR) of randomized controlled trials (RCTs) of immuno-oncology (IO) for first-line (1L) esophageal squamous cell carcinoma (ESCC) in adults patients
Targeted literature review of cost-effectiveness models in relapsed/refractory follicular lymphoma
Abril 2024
BSH (Sociedad Británica de Hematología)
BSH (Sociedad Británica de Hematología)
Abril de 2024 (Liverpool, Reino Unido)
Presentaciones
Pósteres
Acquired mutations in patients with relapsed/refractory chronic lymphocytic leukemia that progressed in the ALPINE study
First results from a phase 1, first-in-human study BGB-16673 in patients with relapsed/refractory B-cell malignancies
Ibrutinib efficacy in ALPINE and ELEVATE-RR trials in relapsed/refractory chronic lymphocytic leukemia: matching-adjusted indirect comparison
Outcomes ≥1 year after transitioning from treatment with ibrutinib in the ASPEN study to zanubrutinib
Sonrotoclax (BGB-11417) monotherapy in patients with relapsed/refractory marginal zone lymphoma: an ongoing phase 1 study
Zanubrutinib in acalabrutinib-intolerant patients with B-cell malignancies
Zanubrutinib vs FCR in fit treatment-naive patients with chronic lymphocytic leukemia: a matching-adjusted indirect comparison
Resúmenes
Acquired mutations in patients with relapsed/refractory chronic lymphocytic leukemia that progressed in the ALPINE study
Extended follow-up of the phase 3 ALPINE study of zanubrutinib versus ibrutinib in R/R CLL/SLL
First results from a phase 1, first-in-human study BGB-16673 in patients with relapsed/refractory B-cell malignancies
Ibrutinib efficacy in ALPINE and ELEVATE-RR trials in relapsed/refractory chronic lymphocytic leukemia: matching-adjusted indirect comparison
Outcomes ≥1 year after transitioning from treatment with ibrutinib in the ASPEN study to zanubrutinib
Sonrotoclax (BGB-11417) + zanubrutinib in patients with treatment-naive CLL/SLL: an ongoing phase 1/2 study
Sonrotoclax (BGB-11417) monotherapy in patients with relapsed/refractory marginal zone lymphoma: an ongoing phase 1 study
Zanubrutinib in acalabrutinib-intolerant patients with B-cell malignancies
Zanubrutinib vs FCR in fit treatment-naive patients with chronic lymphocytic leukemia: a matching-adjusted indirect comparison
Abril 2024
AMCP (Academy of Managed Care Pharmacy)
AMCP (Academy of Managed Care Pharmacy)
Abril de 2024 (Nueva Orleans, Luisiana)
Abril 2024
ISPE (International Society for Pharmacoepidemiology)
ISPE (International Society for Pharmacoepidemiology)
Abril de 2024 (Orlando, Florida)
Abril 2024
AACR (Asociación Estadounidense de Investigación en Cáncer)
AACR (Asociación Estadounidense de Investigación en Cáncer)
Abril de 2024 (San Diego, California, EE. UU.)
Pósteres
A first-in-human, phase 1a, dose-escalation study of BGB-10188, a phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor, + tislelizumab (anti-PD-1) in patients with solid tumors
BGB-A317-LBL-007-202: a phase 2, randomized, active-controlled, open-label study to evaluate the efficacy and safety of LBL-007 (anti-LAG-3) in combination with tislelizumab (TIS; anti-PD-1) plus chemotherapy (chemo) as first-line (1L) treatment in patients with unresectable locally advanced/metastatic esophageal squamous cell carcinoma (ESCC)
BGB-B167, a first-in-class 4-1BB/ CEACAM5 bispecific antibody, exhibits potent in vitro and vivo antitumor activity and superior safety profile in preclinical models
BGB-LC-201 (NCT05635708): a phase 2, open-label, multi-arm study of tislelizumab (TIS; anti-PD-1) in combination with investigational agents +/- chemotherapy as first-line treatment for patients with locally advanced, unresectable, or metastatic non–small cell lung cancer (NSCLC)
Characterization of the correlation between BTK degradation and tumor growth inhibition of the BTK target protein degraders using PK/PD modeling
Exploration of potential biomarkers correlated with efficacy of ociperlimab (anti-TIGIT) plus tislelizumab (anti-PD1) in 1L PD-L1+ non-small cell lung cancer (NSCLC)
Liberty-201: maintenance fluoropyrimidine (FP) and bevacizumab with or without anti-lymphocyte activation gene-3 (LAG-3) antibody LBL-007 plus anti-programmed cell death protein-1 (PD-1) antibody tislelizumab (TIS) for patients (pts) with metastatic or unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) colorectal cancer (CRC)
Translational assessment of triple combination with tislelizumab (anti-PD-1), LBL-007 (anti-LAG-3) and surzebiclimab (anti-TIM-3) highlights its strong anti-tumor activity and clinical potential in solid tumors such as HNSCC
Resúmenes
A first-in-human, phase 1a, dose-escalation study of BGB-10188, a phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor, + tislelizumab (anti-PD-1) in patients with solid tumors
AdvanTIG-204: a phase 2, multicenter, randomized, 3-arm, open-label study investigating the preliminary efficacy and safety of ociperlimab (anti-TIGIT) + tislelizumab (anti-PD-1) + concurrent chemoradiotherapy (cCRT) in patients with untreated limited-stage small cell lung cancer (SCLC)
BGB-A317-LBL-007-202: a phase 2, randomized, active-controlled, open-label study to evaluate the efficacy and safety of LBL-007 (anti-LAG-3) in combination with tislelizumab (TIS; anti-PD-1) plus chemotherapy (chemo) as first-line (1L) treatment in patients with unresectable locally advanced/metastatic esophageal squamous cell carcinoma (ESCC)
BGB-B167, a first-in-class 4-1BB/ CEACAM5 bispecific antibody, exhibits potent in vitro and vivo antitumor activity and superior safety profile in preclinical models
BGB-LC-201 (NCT05635708): a phase 2, open-label, multi-arm study of tislelizumab (TIS; anti-PD-1) in combination with investigational agents +/- chemotherapy as first-line treatment for patients with locally advanced, unresectable, or metastatic non–small cell lung cancer (NSCLC)
Characterization of the correlation between BTK degradation and tumor growth inhibition of the BTK target protein degraders using PK/PD modeling
Exploration of potential biomarkers correlated with efficacy of ociperlimab (anti-TIGIT) plus tislelizumab (anti-PD1) in 1L PD-L1+ non-small cell lung cancer (NSCLC)
Liberty-201: maintenance fluoropyrimidine (FP) and bevacizumab with or without anti-lymphocyte activation gene-3 (LAG-3) antibody LBL-007 plus anti-programmed cell death protein-1 (PD-1) antibody tislelizumab (TIS) for patients (pts) with metastatic or unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) colorectal cancer (CRC)
Translational assessment of triple combination with tislelizumab (anti-PD-1), LBL-007 (anti-LAG-3) and surzebiclimab (anti-TIM-3) highlights its strong anti-tumor activity and clinical potential in solid tumors such as HNSCC
Abril 2024
Hematology/Oncology Pharmacy Association (HOPA)
Hematology/Oncology Pharmacy Association (HOPA)
Abril de 2024 (Tampa, Florida, EE. UU.)
Marzo 2024
Conferencia Internacional de la Sociedad Coreana de Hematología y 65.ª reunión anual (ICKSH)
Conferencia Internacional de la Sociedad Coreana de Hematología y 65.ª reunión anual (ICKSH)
Marzo de 2024 (Seúl, Corea)
Presentaciones
Pósteres
Marzo 2024
44.º Congreso de la Sociedad Francesa de Hematología (SFH)
44.º Congreso de la Sociedad Francesa de Hematología (SFH)
Marzo 2024 (París, Francia)
Presentaciones
Extended follow-up of the phase 3 ALPINE study of zanubrutinib versus ibrutinib in R/R CLL/SLL
First results from a phase 1, first-in-human study BGB-16673 in patients with relapsed/refractory B-cell malignancies
Tislelizumab, an anti–PD-1 antibody, in patients with relapsed/refractory classical Hodgkin lymphoma in TIRHOL BGB-A317-210: A prospective, multicenter, phase 2 LYSA study conducted in Western countries
Pósteres
Acquired mutations in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) that progressed in the ALPINE study
Extended follow-up of the phase 3 ALPINE study of zanubrutinib versus ibrutinib in R/R CLL/SLL
Health-related quality of life (HRQoL) in patients with relapsed/refractory follicular lymphoma (R/R FL) treated with zanubrutinib + obinutuzumab versus obinutuzumab monotherapy: The ROSEWOOD trial
Outcomes ≥1 year after transitioning from treatment with ibrutinib in the ASPEN study to zanubrutinib
Similar ibrutinib efficacy in ALPINE and ELEVATE-RR trials in relapsed/refractory chronic lymphocytic leukemia: Matching-adjusted indirect comparison
Sonrotoclax (BGB-11417) + zanubrutinib in patients with treatment-naive CLL/SLL: An ongoing phase 1/2 study
Tislelizumab, an anti–PD-1 antibody, in patients with relapsed/refractory classical Hodgkin lymphoma in TIRHOL BGB-A317-210: A prospective, multicenter, phase 2 LYSA study conducted in Western countries
Toxicity, progression-free survival, and quality of life of patients treated with zanubrutinib versus ibrutinib: A Q-TWiST analysis from the ALPINE study in relapsed/refractory chronic lymphocytic leukemia
Zanubrutinib in acalabrutinib-intolerant patients with B-cell malignancies
Resúmenes
Acquired mutations in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) that progressed in the ALPINE study
Efficacité similaire de l’ibrutinib dans les essais ALPINE et ELEVATE-RR sur la leucémie lymphoïde chronique en rechute/réfractaire : comparaison indirecte ajustée par appariement
Extended follow-up of ALPINE randomized phase 3 study confirms sustained superior progression-free survival of zanubrutinib versus ibrutinib for treatment of relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL)
First results from a phase 1, first-in-human study of the bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory B-cell malignancies
Health-related quality of life (HRQoL) in patients with relapsed/refractory follicular lymphoma (R/R FL) treated with zanubrutinib + obinutuzumab versus obinutuzumab monotherapy: the ROSEWOOD trial
Le suivi prolongé de l’étude de phase 3 randomisée ALPINE confirme que le zanubrutinib présente une supériorité à long terme sur le plan de la survie sans progression par rapport à l’ibrutinib dans le traitement de la LLC/LPL R/R
Mutations acquises chez des patients atteints de leucémie lymphoïde chronique (LLC) en rechute/réfractaire ayant progressé dans l’étude ALPINE
Outcomes ≥1 year after transitioning from treatment with ibrutinib in the ASPEN study to zanubrutinib
Premiers résultats d’une étude de phase 1 évaluant le BGB-16673, un dégradeur de la tyrosine kinase de Bruton, chez des patients atteints d’hémopathies lymphoïdes B en rechute/réfractaire
Qualité de vie liée (QdV) chez les patients atteints d’un lymphome folliculaire en rechute/réfractaire (LF R/R) traités par zanubrutinib + obinutuzumab par rapport à obinutuzumab en monothérapie : l’essai ROSEWOOD
Résultats à ≥ 1 an chez les patients ayant reçu zanubrutinib après un traitement par ibrutinib dans l’étude ASPEN
Similar ibrutinib efficacy in ALPINE and ELEVATE-RR trials in relapsed/refractory chronic lymphocytic leukemia: matching-adjusted indirect comparison
Sonrotoclax (BGB-11417) + zanubrutinib chez des patients présentant une leucémie lymphoide chronique / un lymphome lymphocytique (LLC/LL) non prétraités : essai de phase 1/2 en cours
Sonrotoclax (BGB-11417) + zanubrutinib in patients with treatment-naive CLL/SLL: an ongoing phase 1/2 study
Tislelizumab, an anti–PD-1 antibody, in patients with relapsed/refractory classical Hodgkin lymphoma in TIRHOL BGB-A317-210: A prospective, multicenter, phase 2 LYSA study conducted in Western countries
Toxicity, progression-free survival, and quality of life of patients treated with zanubrutinib versus ibrutinib: a Q-TWiST analysis from the ALPINE study in relapsed/refractory chronic lymphocytic leukemia
Toxicité, survie sans progression et qualité de vie des patients traités par zanubrutinib par rapport à ibrutinib dans la leucémie lymphoïde chronique en rechute/réfractaire : analyse Q-TWiST de l’étude ALPINE
Zanubrutinib chez des patients intolérants à l’acalabrutinib atteints d’hémopathies lymphoïdes B
Zanubrutinib in acalabrutinib-intolerant patients with B-cell malignancies
Évaluation du tislélizumab, anticorps anti-PD-1, chez des patients atteints d’un lymphome de Hodgkin classique en rechute/ réfractaire : étude prospective multicentrique de phase 2 TIRHOL BGB-A317-210 du LYSA
Marzo 2024
ELCC (Congreso Europeo de Cáncer de Pulmón)
ELCC (Congreso Europeo de Cáncer de Pulmón)
Marzo de 2024 (Praga, República Checa)
Marzo 2024
3.ª Conferencia de Investigación Traslacional de la Escuela Europea de Hematología: Leucemia linfocítica crónica (ESH LLC)
3.ª Conferencia de Investigación Traslacional de la Escuela Europea de Hematología: Leucemia linfocítica crónica (ESH LLC)
Marzo de 2024 (Viena, Austria)
Febrero 2024
Congreso Internacional sobre Neoplasias Hematológicas (ICHM)
Congreso Internacional sobre Neoplasias Hematológicas (ICHM)
Febrero de 2024 (Miami Beach, Florida, EE. UU.)
Pósteres
Efficacy of zanubrutinib versus acalabrutinib in the treatment of relapsed or refractory chronic lymphocytic leukemia (R/R CLL): a matching-adjusted indirect comparison (MAIC)
Real-world Bruton tyrosine kinase inhibitor (BTKi) treatment patterns among patients with CLL/SLL in US community oncology practices
Real-world patterns of care and financial burden among patients with follicular lymphoma in the US
Real-world switching pattern, persistence, and associated healthcare resource utilization of Bruton tyrosine kinase inhibitors for the treatment of mantle cell lymphoma in the United States
Recent patterns of care with BTK inhibitors and distribution of social determinants of health among patients with CLL/SLL in the US community setting
Resúmenes
Efficacy of zanubrutinib versus acalabrutinib in the treatment of relapsed or refractory chronic lymphocytic leukemia (R/R CLL): a matching-adjusted indirect comparison (MAIC)
Real-world Bruton tyrosine kinase inhibitor (BTKi) treatment patterns among patients with CLL/SLL in US community oncology practices
Real-world patterns of care and financial burden among patients with follicular lymphoma in the US
Real-world switching pattern, persistence, and associated healthcare resource utilization of Bruton tyrosine kinase inhibitors for the treatment of mantle cell lymphoma in the United States
Recent patterns of care with BTK inhibitors and distribution of social determinants of health among patients with CLL/SLL in the US community setting
Febrero 2024
JSMO (Sociedad Japonesa de Oncología Médica)
JSMO (Sociedad Japonesa de Oncología Médica)
Febrero de 2024 (Nagoya, Japón)
Febrero 2024
Plenaria virtual de la Sociedad Europea de Oncología Médica (ESMO)
Plenaria virtual de la Sociedad Europea de Oncología Médica (ESMO)
Febrero de 2024 (virtual)
Enero 2024
Congrès de Pneumologie de Langue Française (CPLF)
Congrès de Pneumologie de Langue Française (CPLF)
Enero de 2024 (Lille, Francia)
Enero 2024
Biennale Monégasque de Cancérologie (BMC)
Biennale Monégasque de Cancérologie (BMC)
Enero de 2024 (Mónaco)
Presentaciones
A phase 1 study with the novel B-cell lymphoma 2 inhibitor sonrotoclax (BGB-11417) as monotherapy or in combination with zanubrutinib in patients with CLL/SLL: preliminary data
Long-term efficacy and safety of zanubrutinib in patients with relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA (BGB-3111-214) trial
Resúmenes
A phase 1 study with the novel B-cell lymphoma 2 (Bcl-2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with CLL/SLL: preliminary data
Long-term efficacy and safety of zanubrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL): final analysis of the MAGNOLIA (BGB-3111-214) trial
Enero 2024
ASCO-GI (Sociedad Estadounidense de Oncología Clínica - Simposio de Cánceres Gastrointestinales)
ASCO-GI (Sociedad Estadounidense de Oncología Clínica - Simposio de Cánceres Gastrointestinales)
Enero de 2024 (San Francisco, California, EE. UU.)
Pósteres
Tislelizumab (TIS) plus chemotherapy (chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): health-related quality of life (HRQoL) outcomes in the RATIONALE-305 study
Concordance among three programmed death-ligand 1 (PD-L1) scoring methods and their association with clinical outcomes of tislelizumab (TIS) monotherapy in esophageal squamous cell carcinoma (ESCC)
Tislelizumab plus chemotherapy (chemo) versus placebo plus chemo as first-line treatment for locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma: RATIONALE-305 European/North American patient subgroup
Resúmenes
Tislelizumab (TIS) plus chemotherapy (chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): health-related quality of life (HRQoL) outcomes in the RATIONALE-305 study
Concordance among three programmed death-ligand 1 (PD-L1) scoring methods and their association with clinical outcomes of tislelizumab (TIS) monotherapy in esophageal squamous cell carcinoma (ESCC)
Tislelizumab plus chemotherapy (chemo) versus placebo plus chemo as first-line treatment for locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma: RATIONALE-305 European/North American patient subgroup
Diciembre 2023
ASH (Sociedad Estadounidense de Hematología)
ASH (Sociedad Estadounidense de Hematología)
Diciembre de 2023 (San Diego, California, EE. UU.)
Presentaciones
Combination treatment with sonrotoclax (BGB-11417), a second-generation BCL2 inhibitor, and zanubrutinib, a Bruton tyrosine kinase inhibitor, is well tolerated and achieves deep responses in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma: data from an ongoing phase 1/2 study
Extended follow-up of ALPINE randomized phase 3 study confirms sustained superior progression-free survival of zanubrutinib versus ibrutinib for treatment of relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL)
Sonrotoclax (BGB-11417) in combination with dexamethasone for the treatment of relapsed/refractory multiple myeloma with t(11;14): safety, efficacy, and determination of recommended phase 2 dose
Pósteres
Acquired mutations in patients with relapsed/refractory chronic lymphocytic leukemia who progressed in the ALPINE study
Broad superiority of zanubrutinib over bendamustine + rituximab across multiple high-risk factors: biomarker subgroup analysis in the phase 3 SEQUOIA study in patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma without del(17p)
Clinical outcomes in patients with Waldenström macroglobulinemia (WM) receiving ibrutinib on the phase 3 ASPEN study ≥1 year after transitioning to zanubrutinib
First results from a phase 1, first-in-human study of Bruton's tyrosine kinase (BTK) degrader BGB-16673 in patients (pts) with relapsed or refractory (R/R) B-cell malignancies
Health-related quality of life (HRQoL) in patients with relapsed/refractory follicular lymphoma (R/R FL) treated with zanubrutinib+ obinutuzumab versus obinutuzumab monotherapy: the ROSEWOOD trial
Monotherapy with second-generation BCL2 inhibitor sonrotoclax (BGB-11417) is well tolerated with high response rates in patients with relapsed/refractory marginal zone lymphoma: data from an ongoing phase 1 study
Number needed to treat analyses of zanubrutinib in relapsed/refractory chronic lymphocytic leukemia
Real-world Bruton tyrosine kinase inhibitor (BTKi) treatment patterns among patients with chronic or small lymphocytic leukemia (CLL/SLL) in US community oncology practices
Real-world evaluation of treatment discontinuation and healthcare resource utilization in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma
Real-world patterns of care and financial burden of patients with follicular lymphoma in the United States
Real-world switching pattern, persistence, and associated healthcare resource utilization of Bruton tyrosine kinase inhibitors for the treatment of mantle cell lymphoma in the United States
Recent patterns of care with BTK inhibitors and distribution of social determinants of health among patients with CLL/SLL in the US community setting
Similar efficacy of ibrutinib arms across ALPINE and ELEVATE-RR trials in relapsed/refractory chronic lymphocytic leukemia: a matching-adjusted indirect comparison
Tislelizumab, an anti-PD1 antibody, in patients with relapsed/refractory classical Hodgkin lymphoma in TIRHOL BGB-A317-210: a prospective multicenter Lysa phase 2 study conducted in Western countries
Toxicity, progression-free survival, and quality of life of patients treated with zanubrutinib versus ibrutinib: a Q-TWiST analysis from the ALPINE study in relapsed or refractory chronic lymphocytic leukemia
Zanubrutinib in acalabrutinib-intolerant patients (pts) with B-cell malignancies
Resúmenes
A phase 4, observational study evaluating the efficacy and safety of the Bruton tyrosine kinase inhibitor (BTKi) zanubrutinib in patients with Waldenström macroglobulinemia (WM)
Acquired mutations in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) that progressed in the ALPINE study
Broad superiority of zanubrutinib (zanu) over bendamustine + rituximab (BR) across multiple high-risk factors: Biomarker subgroup analysis in the phase 3 SEQUOIA study in patients with treatment-naive (TN) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) without del(17p)
Clinical outcomes in patients with Waldenström macroglobulinemia (WM) receiving ibrutinib on the phase 3 ASPEN study ≥1 year after transitioning to zanubrutinib
Combination treatment with sonrotoclax (BGB-11417), a second-generation BCL2 inhibitor, and zanubrutinib, a Bruton tyrosine kinase (BTK) inhibitor, is well tolerated and achieves deep responses in patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma (TN-CLL/SLL): data from an ongoing phase 1/2 study
Extended follow-up of ALPINE randomized phase 3 study confirms sustained superior progression-free survival of zanubrutinib versus ibrutinib for treatment of relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL)
First results from a phase 1, first-in-human study of Bruton's tyrosine kinase (BTK) degrader BGB-16673 in patients (pts) with relapsed or refractory (R/R) B-cell malignancies
Genomic landscape of ibrutinib- and/or acalabrutinib-intolerant patients with B-cell malignancies treated with zanubrutinib in a phase 2 study
Health-related quality of life (HRQoL) in patients with relapsed/refractory follicular lymphoma (R/R FL) treated with zanubrutinib+ obinutuzumab versus obinutuzumab monotherapy: the ROSEWOOD trial
Monotherapy with second-generation BCL2 inhibitor sonrotoclax (BGB-11417) is well tolerated with high response rates in patients with relapsed/refractory marginal zone lymphoma: data from an ongoing phase 1 study
Number needed to treat analyses of zanubrutinib in relapsed/refractory chronic lymphocytic leukemia
Real-world Bruton tyrosine kinase inhibitor (BTKi) treatment patterns among patients with chronic or small lymphocytic leukemia (CLL/SLL) in US community oncology practices
Real-world evaluation of treatment discontinuation and healthcare resource utilization in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma
Real-world patterns of care and financial burden of patients with follicular lymphoma in the United States
Real-world switching pattern, persistence, and associated healthcare resource utilization of Bruton tyrosine kinase inhibitors for the treatment of mantle cell lymphoma in the United States
Recent patterns of care with BTK inhibitors and distribution of social determinants of health among patients with CLL/SLL in the US community setting
Similar efficacy of ibrutinib arms across ALPINE and ELEVATE-RR trials in relapsed/refractory chronic lymphocytic leukemia: a matching-adjusted indirect comparison
Sonrotoclax (BGB-11417) in combination with dexamethasone for the treatment of relapsed/refractory multiple myeloma with t(11;14): safety, efficacy, and determination of recommended phase 2 dose
Tislelizumab, an anti-PD1 antibody, in patients with relapsed/refractory classical Hodgkin lymphoma in TIRHOL BGB-A317-210: a prospective multicenter Lysa phase 2 study conducted in Western countries
Toxicity, progression-free survival, and quality of life of patients treated with zanubrutinib versus ibrutinib: a Q-TWiST analysis from the ALPINE study in relapsed or refractory chronic lymphocytic leukemia
Zanubrutinib in acalabrutinib-intolerant patients (pts) with B-cell malignancies
Zanubrutinib vs FCR in fit treatment-naive patients with chronic lymphocytic leukemia: a matching-adjusted indirect comparison
Diciembre 2023
ESMO-IO (Inmunooncología de la Sociedad Europea de Oncología Médica)
ESMO-IO (Inmunooncología de la Sociedad Europea de Oncología Médica)
Diciembre 2023 (Ginebra, Suiza)
Pósteres
BGB-HNSCC-201 (NCT05909904): Phase 2, open-label, multi-arm, global study of tislelizumab (tis) + investigational agents as first-line (1L) treatment in patients (Pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC)
Exploratory analysis of peripheral pharmacodynamic (PD) biomarkers after sitravatinib (Sitra) and tislelizumab (TIS) in advanced solid tumors: SAFFRON-103
Resúmenes
BGB-HNSCC-201 (NCT05909904): Phase 2, open-label, multi-arm, global study of tislelizumab (tis) + investigational agents as first-line (1L) treatment in patients (Pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC)
Exploratory analysis of peripheral pharmacodynamic (PD) biomarkers after sitravatinib (Sitra) and tislelizumab (TIS) in advanced solid tumors: SAFFRON-103
Noviembre 2023
ESMO-Asia (Sociedad Europea de Oncología Médica - Asia)
ESMO-Asia (Sociedad Europea de Oncología Médica - Asia)
Noviembre 2023 (Singapur)
Presentaciones
Pooled safety analysis of zanubrutinib in Asian patients with B-cell malignancies
Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1l) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): final analysis results of the RATIONALE-305 study
Zanidatamab (ZW25; Zani) in Patients (pts) with previously treated advanced human epidermal growth factor receptor 2 (HER2)-amplified biliary tract cancer (BTC): Asia subgroup analysis of the Phase 2b HERIZON-BTC-01 study
Pósteres
BGB-LC-202 (NCT05577702): Phase 2 Umbrella study of tislelizumab (TIS) monotherapy and tis-based immunotherapy combinaons +/- chemotherapy (CT) as neoadjuvant treatment in chinese paents (pts) with resectable Stage II to IIIA non-small cell lung cancer (NSCLC)
Tislelizumab (TIS) + chemotherapy (Chemo)/chemoradiotherapy (CRT) as Neoadjuvant treatment for resectable esophageal squamous cell carcinoma (R-ESCC)
Resúmenes
BGB-LC-202 (NCT05577702): Phase 2 Umbrella study of tislelizumab (TIS) monotherapy and tis-based immunotherapy combinaons +/- chemotherapy (CT) as neoadjuvant treatment in chinese paents (pts) with resectable Stage II to IIIA non-small cell lung cancer (NSCLC)
Pooled safety analysis of zanubrutinib monotherapy in Asian patients with B-cell malignancies
Tislelizumab (TIS) + chemotherapy (Chemo)/chemoradiotherapy (CRT) as Neoadjuvant treatment for resectable esophageal squamous cell carcinoma (R-ESCC)
Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1l) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): final analysis results of the RATIONALE-305 study
Zanidatamab (ZW25; Zani) in Patients (pts) with previously treated advanced human epidermal growth factor receptor 2 (HER2)-amplified biliary tract cancer (BTC): Asia subgroup analysis of the Phase 2b HERIZON-BTC-01 study
Noviembre 2023
AGITG (Grupo de Ensayos Gastrointestinales de Australasia)
AGITG (Grupo de Ensayos Gastrointestinales de Australasia)
Noviembre de 2023 (Christchurch, Nueva Zelanda)
Noviembre 2023
ISPOR-EU (Sociedad Internacional de Farmacoeconomía e Investigación de Resultados - Europa)
ISPOR-EU (Sociedad Internacional de Farmacoeconomía e Investigación de Resultados - Europa)
Noviembre 2023 (Copenhague, Dinamarca)
Pósteres
Bruton tyrosine kinase inhibitor (BTKi) monotherapy for the treatment of ‘high-risk’ patients with previously untreated chronic lymphocytic leukemia (CLL): a systematic literature review (SLR)
Cost-minimization analysis (CMA) of Bruton tyrosine kinase inhibitors (BTKis) in adults with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)
Cost-utility analysis (CUA) in chronic lymphocytic leukemia (CLL): Is COVID-19’s impact on national life tables important to consider?
Global clinical, economic, health-related quality of life burden, and treatment outcomes in follicular lymphoma: a systematic review
Incidence, prevalence, and clinical characteristics of patients with chronic lymphocytic leukemia (CLL) in Spain: natural language processing (NLP) analysis of electronic health records (EHRs)
Psychometric validation of QLQ-OES18 in 2L esophageal squamous cell cancer (ESCC) patients treated with tislelizumab versus chemotherapy
Q-TWiST analysis is back in the game in oncology clinical trial analysis: a recent trend
Quality of life and economic burden of advanced non-small cell lung cancer in medium and small markets (MED&SM): a systematic literature review
Targeted treatments for patients with relapsed and/or refractory (R/R) chronic lymphocytic leukemia (CLL): a systematic literature review (SLR) of randomized clinical trials (RCTs)
The disease and economic burden of hepatocellular carcinoma in Australia
Treatment patterns and adverse events (AEs) in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in France, Italy, and the United Kingdom (UK)
Unmet needs and evidence gaps in relapsed/refractory marginal zone lymphoma: findings from a systematic literature review
Resúmenes
Bruton tyrosine kinase inhibitor (BTKi) monotherapy for the treatment of ‘high-risk’ patients with previously untreated chronic lymphocytic leukemia (CLL): a systematic literature review (SLR)
Cost-minimization analysis (CMA) of Bruton tyrosine kinase inhibitors (BTKis) in adults with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)
Cost-utility analysis (CUA) in chronic lymphocytic leukemia (CLL): Is COVID-19’s impact on national life tables important to consider?
Global clinical, economic, health-related quality of life burden, and treatment outcomes in follicular lymphoma: a systematic review
Incidence, prevalence, and clinical characteristics of patients with chronic lymphocytic leukemia (CLL) in Spain: natural language processing (NLP) analysis of electronic health records (EHRs)
Psychometric validation of QLQ-OES18 in 2L esophageal squamous cell cancer (ESCC) patients treated with tislelizumab versus chemotherapy
Q-TWiST analysis is back in the game in oncology clinical trial analysis: a recent trend
Quality of life and economic burden of advanced non-small cell lung cancer in medium and small markets (MED&SM): a systematic literature review
Targeted treatments for patients with relapsed and/or refractory (R/R) chronic lymphocytic leukemia (CLL): a systematic literature review (SLR) of randomized clinical trials (RCTs)
The disease and economic burden of hepatocellular carcinoma in Australia
Treatment patterns and adverse events (AEs) in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in France, Italy, and the United Kingdom (UK)
Unmet needs and evidence gaps in relapsed/refractory marginal zone lymphoma: findings from a systematic literature review
Noviembre 2023
SPH (Sociedad Portuguesa de Hematología)
SPH (Sociedad Portuguesa de Hematología)
Noviembre de 2023 (Viseu, Portugal)
Pósteres
Resúmenes
Noviembre 2023
Asamblea Científica Anual de BLOOD (BLOOD)
Asamblea Científica Anual de BLOOD (BLOOD)
Noviembre 2023 (Melbourne, Australia)
Presentaciones
A phase 1 study with the novel B-cell lymphoma 2 (Bcl-2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with NHL, or Waldenström macroglobulinemia (WM): preliminary data
Incidence, prevalence, and mortality of Waldenström macroglobulinemia (WM) in Australia
Long-term efficacy and safety of zanubrutinib in patients with relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA (BGB-3111-214) trial
Pósteres
A phase 1 study with the novel B-cell lymphoma 2 (Bcl-2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with CLL/SLL: preliminary data
Characterization of the safety/tolerability profile of zanubrutinib and comparison with the profile of ibrutinib in patients with B-cell malignancies: post hoc analysis of a large clinical trial safety database
Health-related quality of life (HRQOL) in patients with Waldenström macroglobulinemia (WM) treated with zanubrutinib or ibrutinib: results from long-term follow-up of the phase 3 ASPEN trial
Incidence, prevalence, and mortality of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in Australia
Zanubrutinib demonstrates superior progression-free survival (PFS) vs ibrutinib for treatment of relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): final analysis of randomized phase 3 ALPINE study
Zanubrutinib plus obinutuzumab vs obinutuzumab in patients with relapsed/refractory follicular lymphoma: updated analysis of the ROSEWOOD study
Zanubrutinib vs bendamustine + rituximab (BR) in patients with treatment-naive (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): extended follow-up of the SEQUOIA study
Zanubrutinib vs ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): impact on health-related quality of life (HRQOL)
Resúmenes
A phase 1 study with the novel B-cell lymphoma 2 (Bcl-2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with CLL/SLL: preliminary data
A phase 1 study with the novel B-cell lymphoma 2 (Bcl-2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with NHL, or Waldenström macroglobulinemia (WM): preliminary data
Characterization of the safety/tolerability profile of zanubrutinib and comparison with the profile of ibrutinib in patients with B-cell malignancies: post hoc analysis of a large clinical trial safety database
Health-related quality of life (HRQOL) in patients with Waldenström macroglobulinemia (WM) treated with zanubrutinib or ibrutinib: results from long-term follow-up of the phase 3 ASPEN trial
Incidence, prevalence, and mortality of Waldenström macroglobulinemia (WM) in Australia
Incidence, prevalence, and mortality of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in Australia
Long-term efficacy and safety of zanubrutinib in patients with relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA (BGB-3111-214) trial
Zanubrutinib demonstrates superior progression-free survival (PFS) vs ibrutinib for treatment of relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): final analysis of randomized phase 3 ALPINE study
Zanubrutinib plus obinutuzumab vs obinutuzumab in patients with relapsed/refractory follicular lymphoma: updated analysis of the ROSEWOOD study
Zanubrutinib vs bendamustine + rituximab (BR) in patients with treatment-naive (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): extended follow-up of the SEQUOIA study
Zanubrutinib vs ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): impact on health-related quality of life (HRQOL)
Noviembre 2023
American Society of Nephrology Kidney Week (ASN Kidney Week)
American Society of Nephrology Kidney Week (ASN Kidney Week)
Noviembre de 2023 (Filadelfia, Pensilvania, EE. UU.)
Noviembre 2023
Asamblea Anual de Japan Lung Cancer Society (JLCS)
Asamblea Anual de Japan Lung Cancer Society (JLCS)
Noviembre de 2023 (Chiba, Japón)
Octubre 2023
SEHH (Sociedad Española de Hematología y Hemoterapia)
SEHH (Sociedad Española de Hematología y Hemoterapia)
Octubre de 2023 (Sevilla, España)
Presentaciones
Zanubrutinib (ZANU) vs bendamustine + rituximab (BR) in patients (pts) with treatment-naive (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): extended follow-up of the SEQUOIA study
Zanubrutinib (zanu) in relation to ibrutinib (ibr) improves PFS in patients with refractory/recurrent (R/R) CLL: final analysis of the ALPINE study
Pósteres
Evaluation of treatment and safety patterns in patients with chronic lymphocytic leukemia (CLL) using natural language processing (NLP): perspective of a multicenter observational study in Spain
Health-related quality of life in patients (Pts) with Waldenström macroglobulinemia (WM) treated with zanubrutinib (ZANU) vs ibrutinib (IBR): phase 3 ASPEN trial long-term follow-up results
Phase 1 study with the novel B-cell lymphoma 2 (Bcl-2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib for CLL/SLL: preliminary data
Phase 1 study with the novel Bcl-2 inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib for NHL or Waldenström macroglobulinemia (WM): preliminary data
Zanubrutinib plus obinutuzumab vs obinutuzumab in patients with relapsed/refractory follicular lymphoma: updated analysis of the ROSEWOOD study
Zanubrutinib vs ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): impact on health-related quality of life (HRQoL)
Resúmenes
Evaluation of treatment and safety patterns in patients with chronic lymphocytic leukemia (CLL) using natural language processing (NLP): perspective of a multicenter observational study in Spain
Health-related quality of life in patients (pts) with Waldenström macroglobulinemia (WM) treated with zanubrutinib (zanu) vs ibrutinib (ibr): phase 3 ASPEN trial long-term follow-up results
MAHOGANY: phase III trial of zanubrutinib (Z) plus anti-CD20 antibodies against lenalidomide plus rituximab (L+R) in patients (pts.) with relapsed/refractory follicular lymphoma (FL) or marginal zone lymphoma (MZL) (R/R)
Phase 1 study with the novel B-cell lymphoma 2 (Bcl-2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib for CLL/SLL: preliminary data
Phase 1 study with the novel Bcl-2 inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib for NHL or Waldenström macroglobulinemia (WM): preliminary data
Zanubrutinib (ZANU) vs bendamustine + rituximab (BR) in patients (pts) with treatment-naive (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): extended follow-up of the SEQUOIA study
Zanubrutinib (zanu) in relation to ibrutinib (ibr) improves PFS in patients with refractory/recurrent (R/R) CLL: final analysis of the ALPINE study
Zanubrutinib plus obinutuzumab vs obinutuzumab in patients with relapsed/refractory follicular lymphoma: updated analysis of the ROSEWOOD study
Zanubrutinib vs ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): impact on health-related quality of life (HRQoL)
Octubre 2023
SIE (Sociedad Italiana de Hematología)
SIE (Sociedad Italiana de Hematología)
Octubre de 2023 (Roma, Italia)
Presentaciones
A phase 1 study with the novel B-cell lymphoma 2 inhibitor sonrotoclax (BGB-11417) as monotherapy or in combination with zanubrutinib (zanu) in patients (pts) with CLL/SLL: preliminary data
Updated safety and efficacy results of zanubrutinib in patients with B-cell malignancies who are intolerant of ibrutinib and/or acalabrutinib
Zanubrutinib (zanu) demonstrates superior progression-free survival vs ibrutinib for treatment of R/R CLL/SLL: final analysis of phase 3 ALPINE study
Zanubrutinib (zanu) vs bendamustine + rituximab (BR) in patients with treatment-naive (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): extended follow-up of the SEQUOIA study
Zanubrutinib + obinutuzumab vs obinutuzumab in patients with R/R FL: updated analysis of the ROSEWOOD study
Pósteres
A phase 1 study with the novel B-cell lymphoma 2 inhibitor sonrotoclax (BGB-11417) as monotherapy or in combination with zanubrutinib in patients with non-Hodgkin lymphoma or Waldenström macroglobulinemia: preliminary data
Health-related quality of life in patients (pts) with Waldenström macroglobulinemia (WM) treated with zanubrutinib (zanu) vs ibrutinib (ibr): results from the phase 3 ASPEN trial long-term follow-up
Long-term efficacy and safety of zanubrutinib (zanu) in patients (pts) with relapsed/refractory (R/R) marginal zone lymphoma (R/R MZL): final analysis of the MAGNOLIA (BGB-3111-214) trial
MAHOGANY: a phase 3 trial of zanubrutinib plus anti-CD20 antibodies vs lenalidomide plus rituximab in patients (pts) with relapsed or refractory follicular or marginal zone lymphoma
Zanubrutinib vs ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: impact on health-related quality of life
Resúmenes
Zanubrutinib vs ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): impact on health-related quality of life (HRQoL)
A phase 1 study with the novel B-cell lymphoma 2 (BCL-2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib (zanu) in patients (pts) with CLL/SLL: preliminary data
A phase 1 study with the novel B-cell lymphoma 2 (BCL-2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib (zanu) in patients (pts) with non-Hodgkin lymphoma (NHL) or Waldenström macroglobulinemia (WM): preliminary data
Health-related quality of life in patients (pts) with Waldenström macroglobulinemia (WM) treated with zanubrutinib (zanu) vs ibrutinib (ibr): results from the phase 3 ASPEN trial long-term follow-up
Long-term efficacy and safety of zanubrutinib (zanu) in patients (pts) with relapsed/refractory (R/R) marginal zone lymphoma (MZL): final analysis of the MAGNOLIA (BGB-3111-214) trial
MAHOGANY: a phase 3 trial of zanubrutinib plus anti-CD20 antibodies vs lenalidomide plus rituximab in patients (pts) with relapsed or refractory (R/R) follicular or marginal zone lymphoma (FL or MZL)
Updated safety and efficacy results of zanubrutinib (zanu) in patients with B-cell malignancies who are intolerant of ibrutinib (ibr) and/or acalabrutinib (aca)
Zanubrutinib (zanu) demonstrates superior progression-free survival (PFS) vs ibrutinib (ibr) for treatment of relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): final analysis of phase 3 ALPINE study
Zanubrutinib (zanu) vs bendamustine + rituximab (BR) in patients (pts) with treatment-naive (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): extended follow-up of the SEQUOIA study
Zanubrutinib plus obinutuzumab vs obinutuzumab in patients with relapsed/refractory follicular lymphoma: updated analysis of the ROSEWOOD study
Octubre 2023
Sesión de otoño de Florida Society of Clinical Oncology (FLASCO)
Sesión de otoño de Florida Society of Clinical Oncology (FLASCO)
Octubre de 2023 (Orlando, Florida, EE. UU.)
Octubre 2023
ESMO (Sociedad Europea de Oncología Médica)
ESMO (Sociedad Europea de Oncología Médica)
Octubre 2023 (Madrid, España)
Presentaciones
AdvanTIG-203: phase 2 randomized, multicenter study of ociperlimab (oci) + tislelizumab (tis) in patients (pts) with unresectable, locally advanced, recurrent/metastatic esophageal squamous cell carcinoma (ESCC) and programmed cell death-ligand 1 (PDL1) positivity
AdvanTIG-202: Phase 2 randomized, multicenter, open-label study of tislelizumab (tis) with or without ociperlimab (oci) in patients (pts) with previously treated recurrent/metastatic (r/m) cervical cancer (CC)
AdvanTIG-206: phase 2 randomized open-label study of ociperlimab (oci) + tislelizumab (tis) + BAT1706 (bevacizumab biosimilar) Versus tis + BAT1706 in Patients (pts) with advanced hepatocellular carcinoma (HCC)
Pathological response to neoadjuvant tislelizumab plus platinum-doublet chemotherapy in resectable stage II-IIIa NSCLC patients in the phase 3 RATIONALE-315 trial
View Summary of Presentation in Plain Language
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma: final analysis results of the RATIONALE-305 study
View Summary of Presentation in Plain Language
Pósteres
AdvanTIG-105: phase 1b dose-expansion study of ociperlimab (oci) + tislelizumab (tis) with chemotherapy (ct) in patients (pts) with metastatic esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC)
Long-term follow-up of a Phase 2 Study of tislelizumab (tis) monotherapy in patients (pts) with previously treated, locally advanced, unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) solid tumors
Phase (Ph) 1/2 study of sitravatinib (sitra) alone or with tislelizumab (tis) in advanced hepatocellular carcinoma (HCC) and gastric/gastroesophageal junction cancer (GC/GEJC)
Randomized, global, Phase 3 study of tislelizumab (tis) + chemotherapy (chemo) vs placebo (pbo) + chemo as first-line (1l) treatment for advanced/metastatic esophageal squamous cell carcinoma (ESCC): RATIONALE-306
Zanidatamab (zani) plus chemotherapy (chemo) and tislelizumab (tis) as first-line (1l) therapy for patients (pts) with advanced HER2-positive (+) gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): updated results from a phase 1b/2 study
Resúmenes
AdvanTIG-203: phase 2 randomized, multicenter study of ociperlimab (oci) + tislelizumab (tis) in patients (pts) with unresectable, locally advanced, recurrent/metastatic esophageal squamous cell carcinoma (ESCC) and programmed cell death-ligand 1 (PDL1) positivity
AdvanTIG-105: phase 1b dose-expansion study of ociperlimab (oci) + tislelizumab (tis) with chemotherapy (ct) in patients (pts) with metastatic esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC)
AdvanTIG-202: phase 2 randomized, multicenter, open-label study of tislelizumab (tis) with or without ociperlimab (oci) in patients (pts) with previously treated recurrent/metastatic (r/m) cervical cancer (CC)
AdvanTIG-206: phase 2 randomized open-label study of ociperlimab (oci) + tislelizumab (tis) + BAT1706 (bevacizumab biosimilar) Versus tis + BAT1706 in Patients (pts) with advanced hepatocellular carcinoma (HCC)
Long-term follow-up of a phase 2 study of tislelizumab (tis) monotherapy in patients (pts) with previously treated, locally advanced, unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) solid tumors
Pathological response to neoadjuvant tislelizumab (tis) plus platinum-doublet (PtDb) chemotherapy (CT) in resectable stage II-IIIa NSCLC patients (pts) in the phase 3 (Ph3) RATIONALE-315 trial
Phase (Ph) 1/2 study of sitravatinib (sitra) alone or with tislelizumab (tis) in advanced hepatocellular carcinoma (HCC) and gastric/gastroesophageal junction cancer (GC/GEJC)
Randomized, global, phase 3 study of tislelizumab (tis) + chemotherapy (chemo) vs placebo (pbo) + chemo as first-line (1l) treatment for advanced/metastatic esophageal squamous cell carcinoma (ESCC): RATIONALE-306
Tislelizumab (TIS) plus chemotherapy (chemo) vs placebo (pbo) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): final analysis results of the RATIONALE-305 study
Zanidatamab (zani) plus chemotherapy (chemo) and tislelizumab (tis) as first-line (1l) therapy for patients (pts) with advanced HER2-positive (+) gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): updated results from a phase 1b/2 study
Octubre 2023
JSCO (Sociedad Japonesa de Oncología Clínica)
JSCO (Sociedad Japonesa de Oncología Clínica)
Octubre de 2023 (Yokohama, Japón)
Octubre 2023
DGHO (Sociedades Alemana, Austríaca y Suiza de Hematología y Oncología Médica)
DGHO (Sociedades Alemana, Austríaca y Suiza de Hematología y Oncología Médica)
Octubre de 2023 (Hamburgo, Alemania)
Octubre 2023
JSH (Sociedad Japonesa de Hematología)
JSH (Sociedad Japonesa de Hematología)
Octubre de 2023 (Tokio, Japón)
Presentaciones
Octubre 2023
iwCLL (Taller Internacional sobre LLC)
iwCLL (Taller Internacional sobre LLC)
Octubre de 2023 (Boston, Massachusetts, EE. UU.)
Pósteres
A phase 2 study of zanubrutinib in previously treated B-cell malignancies intolerant to ibrutinib and/or acalabrutinib: preliminary results for patients with CLL/SLL
Characterization of the safety/tolerability profile of zanubrutinib and comparison with the profile of ibrutinib in patients with B-cell malignancies: post hoc analysis of a large clinical trial safety database
Zanubrutinib vs bendamustine + rituximab (BR) in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma: extended follow-up of the SEQUOIA study
Zanubrutinib vs ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): impact on health-related quality of life (HRQoL)
Resúmenes
A phase 2 study of zanubrutinib in previously treated B-cell malignancies intolerant to ibrutinib and/or acalabrutinib: preliminary results for patients with CLL/SLL
Characterization of the safety/tolerability profile of zanubrutinib and comparison with the profile of ibrutinib in patients with B-cell malignancies: post hoc analysis of a large clinical trial safety database
Zanubrutinib vs bendamustine + rituximab (BR) in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma: extended follow-up of the SEQUOIA study
Zanubrutinib vs ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): impact on health-related quality of life (HRQoL)
Septiembre 2023
IMS (Sociedad Internacional de Mieloma)
IMS (Sociedad Internacional de Mieloma)
Septiembre de 2023 (Atenas, Grecia)
Septiembre 2023
Sociedad Española de Oncología Médica (SEOM)
Sociedad Española de Oncología Médica (SEOM)
Septiembre 2023 (Barcelona, España)
Septiembre 2023
PTHiT (Sociedad Polaca de Hematología y Medicina Transfusional)
PTHiT (Sociedad Polaca de Hematología y Medicina Transfusional)
Septiembre de 2023 (Katowice, Polonia)
Presentaciones
Zanubrutinib demonstrated superior progression-free survival vs ibrutinib for treatment of relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: final analysis of phase 3 ALPINE study
Zanubrutinib plus obinutuzumab vs obinutuzumab in patients with relapsed/refractory follicular lymphoma: updated analysis of the ROSEWOOD study
Pósteres
MAHOGANY: A phase 3 trial of zanubrutinib plus anti-CD20 antibodies vs lenalidomide plus rituximab in patients with relapsed or refractory follicular or marginal zone lymphoma
Updated safety and efficacy results of zanubrutinib in patients with B-cell malignancies who are intolerant of ibrutinib and/or acalabrutinib
Resúmenes
MAHOGANY: A phase 3 trial of zanubrutinib plus anti-CD20 antibodies vs lenalidomide plus rituximab in patients with relapsed or refractory follicular or marginal zone lymphoma
Updated safety and efficacy results of zanubrutinib in patients with B-cell malignancies who are intolerant of ibrutinib and/or acalabrutinib
Zanubrutinib demonstrated superior progression-free survival vs ibrutinib for treatment of relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: final analysis of phase 3 ALPINE study
Zanubrutinib plus obinutuzumab vs obinutuzumab in patients with relapsed/refractory follicular lymphoma: updated analysis of the ROSEWOOD study
Septiembre 2023
WCLC (World Conference on Lung Cancer)
WCLC (World Conference on Lung Cancer)
Septiembre de 2023 (Singapur)
Presentaciones
Septiembre 2023
KSMO (Sociedad Coreana de Oncología Médica)
KSMO (Sociedad Coreana de Oncología Médica)
Septiembre de 2023 (Seúl, Corea del Sur)